
==== Front
J Nanobiotechnology
J Nanobiotechnology
Journal of Nanobiotechnology
1477-3155
BioMed Central London

39227831
2793
10.1186/s12951-024-02793-x
Review
The application of bacteria-nanomaterial hybrids in antitumor therapy
Xiao Susu
Mu Min
Feng Chenqian
Pan Shulin
Chen Nianyong n_ychen@hotmail.com

https://ror.org/011ashp19 grid.13291.38 0000 0001 0807 1581 Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041 China
4 9 2024
4 9 2024
2024
22 5361 7 2024
20 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Adverse effects and multidrug resistance remain significant obstacles in conventional cancer therapy. Nanomedicines, with their intrinsic properties such as nano-sized dimensions and tunable surface characteristics, have the potential to mitigate the side effects of traditional cancer treatments. While nanomaterials have been widely applied in cancer treatment, challenges such as low targeting efficiency and poor tumor penetration persist. Recent research has shown that anaerobic bacteria exhibit high selectivity for primary tumors and metastatic cancers, offering good safety and superior tumor penetration capabilities. This suggests that combining nanomaterials with bacteria could complement their respective limitations, opening vast potential applications in cancer therapy. The use of bacteria in combination with nanomaterials for anticancer treatments, including chemotherapy, radiotherapy, and photothermal/photodynamic therapy, has contributed to the rapid development of the field of bacterial oncology treatments. This review explores the mechanisms of bacterial tumor targeting and summarizes strategies for synthesizing bacterial-nanomaterial and their application in cancer therapy. The combination of bacterial-nanomaterial hybrids with modern therapeutic approaches represents a promising avenue for future cancer treatment research, with the potential to improve treatment outcomes for cancer patients.

Graphical Abstract

Keywords

Bacteria
Nanomaterials
Antitumor therapy
Tumor targeting
Hypoxia
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Cancer remains a leading cause of death globally, posing a significant threat to human health [1]. The development of effective cancer treatments is hampered by the complexity and heterogeneity of tumor biology [2–4]. While traditional chemotherapy has played a crucial role in prolonging patient survival, its lack of tumor-specific targeting often leads to suboptimal drug concentrations at the tumor site, diminishing therapeutic efficacy [5–7]. Furthermore, the systemic distribution of most chemotherapy drugs results in toxicity and various adverse effects, including myelosuppression, mucositis, and organ dysfunction [8–11]. These limitations highlight the urgent need for targeted drug delivery methods in cancer therapy. [12]. Current research in cancer therapeutics focuses on enhancing the targeting specificity and delivery efficiency of anticancer agents while simultaneously minimizing adverse effects. The development of nanotechnology over the past few decades has led to the emergence of numerous promising biomedical materials. Nanomaterials have been extensively explored for improving cancer diagnosis and treatment due to their unique physicochemical properties, including nano-scale size, tunable surface characteristics, and capabilities for encapsulation and controlled drug release [2, 13]. This has significantly advanced cancer therapy research. Compared to traditional chemotherapy drugs, nanomedicines offer significant advantages in prolonging drug half-life, enhancing drug stability, bioavailability, and tumor accumulation [14–16]. These characteristics can be utilized to design targeted drug delivery systems, improving the bio-distribution and tumor accumulation of free drugs, thereby enhancing the effectiveness of traditional cancer therapy [17, 18]. Research has demonstrated that nanomedicines can significantly enhance drug retention and permeability, effectively targeting tumor tissues [19]. Additionally, nanomedicines enhance drug efficacy by increasing the local drug concentration in tumors while reducing damage to healthy cells [20]. However, the efficiency of nanoparticle-based tumor targeting is reduced due to the unique physiological structures of the tumor microenvironment, such as dense stroma, heterogeneous vascular leakage, and hypoxic conditions [21–23]. As the transport of nanoparticles primarily relies on passive accumulation in tumor sites through systemic circulation, lacking active driving forces to penetrate deep into tumors, the application of nanoparticles alone in cancer treatment is limited, thus reducing therapeutic efficacy [24].

In response to the limitations of traditional chemotherapy drugs and nanomedicines, recent research has explored novel strategies for cancer therapy utilizing bacteria [25]. The use of bacteria in cancer treatment dates back decades, with American physician William Coley being the first to document the application of bacteria and bacterial toxins for this purpose [26]. In recent years, bacterial therapy has emerged as a promising antitumor strategy. Whether used alone or in combination with traditional anti-cancer treatments, bacterial therapy has demonstrated promising efficacy in promoting tumor regression and inhibiting cancer cell metastasis [27]. The biocompatibility of bacterial therapy has also been widely validated [28–32]. Bacteria themselves possess certain antitumor effects. For instance, bacterial proliferation at tumor sites can compete with cancer cells for nutrients in the tumor microenvironment, thereby restricting tumor growth [33]. Furthermore, the intrinsic pro-inflammatory capacity of bacteria can stimulate the body’s immune system, enhancing the efficacy of immunotherapy [34]. By introducing specific functional plasmids into bacteria to serve as bioreactors for producing cytotoxins, antigenic substances, etc., bacteria can also exert their antitumor effects [35–37]. Additionally, due to the prolonged hypoxic conditions in the tumor microenvironment, obligate or facultative anaerobic bacteria exhibit excellent targeting and colonization abilities towards hypoxic regions of tumors [38, 39]. Many bacteria have been observed to selectively localize and grow at tumor sites, including Escherichia coli, Listeria monocytogenes, Clostridium species, Salmonella species, and Bifidobacterium, demonstrating their colonization capabilities at tumor sites [31, 32, 40–46]. Isolated native intratumoral bacteria exhibit high biocompatibility in mice and antitumor effectiveness with excellent tumor selectivity through a single administration [47]. Bacteria-mediated tumor targeting offers a promising strategy for cancer therapy, particularly when combined with other anti-cancer therapies. This approach can significantly reduce side effects by improving drug targeting, thereby enhancing the efficacy of cancer treatment.

Researchers have extensively studied the mechanisms of using bacteria as carriers for cancer therapy, confirming that bacteria, when injected into tumors or systemically, can track the tumor microenvironment and colonize at tumor sites, contributing to tumor regression [48]. Therefore, scientists utilize the inherent anaerobic targeting of anaerobic microorganisms as drug delivery carriers to transport therapeutic agents to hypoxic regions of tumors [49, 50]. This approach involves attaching drugs to bacteria, thereby achieving targeted cancer therapy. Commonly used bacterial carriers for tumor therapy include Salmonella typhimurium, Bifidobacterium, and Escherichia coli. Studies have shown that the combination of nanotechnology with attenuated strains of Salmonella has been successfully applied in the treatment of melanoma [26, 51]. Furthermore, liposomes attached to different types of bacteria have also shown promising results in cancer therapy and diagnosis [52]. Due to their unique anaerobic targeting capabilities, anaerobic bacteria-mediated tumor-targeted therapy presents a novel and effective strategy for cancer treatment. Many studies have utilized certain bacteria as drug carriers, including anticancer drugs and transport vehicles for drug-loaded nanomaterials, to more effectively target tumors and enhance the anticancer efficacy of conventional drugs [53]. Therefore, bacterial carriers are emerging as a frontier in drug delivery [42]. The autonomous movement and anaerobic targeting ability of bacteria are utilized to transport nanomedicines to the deep regions of solid tumors, while nanomaterials can be attached to bacteria surfaces in various ways, forming bacteria-nanoparticle hybrids to mediate nanoparticle delivery [54]. This bacteria-nanoparticle hybrid approach for cancer therapy has led to rapid advancements in bacterial research for tumor treatment. The application of bacteria as carriers for nanomedicines is also attracting increasing attention from researchers in the field of new anticancer drug development. This review delves into the mechanisms underlying bacteria-mediated tumor targeting. It summarizes synthetic strategies for nano-bacteria hybrids and elaborates on their applications in cancer therapy (Scheme 1). By providing a comprehensive and integrated overview of nano-bacteria hybrids, this review explores their potential future development directions. Ultimately, it aims to offer valuable insights and guidance for researchers in related fields, facilitating their research and development of bacterial nanomaterial hybrids.

Scheme 1 Bacteria can be conjugated with nanomaterials through various strategies for diverse applications in antitumor therapy. Created with BioRender.com

Mechanisms of bacterial targeting and colonization in tumors

Due to their unique properties, bacteria have shown great potential as delivery vectors for targeting drugs and genes to tumor sites [55, 56]. Various bacteria such as Bifidobacterium, Salmonella, Escherichia coli, and Clostridium can selectively accumulate and replicate in hypoxic tumor regions, delivering functional nanoparticles to the target tissue [57, 58]. Table 1 summarizes the bacterial types most investigated for antitumor therapy. Through synthetic biology and genetic engineering, these bacteria can be engineered to precisely deliver anticancer drugs, specific proteins, antibodies, enzymes, antigens, and cytokines [37]. Several factors contribute to the specific targeting and colonization of tumors by bacteria. Solid tumors often exhibit hypoxic regions, a condition prevalent within the tumor microenvironment (TME) [59]. This hypoxic environment is attractive for the colonization and proliferation of anaerobic or facultative anaerobic bacteria [60]. Necrotic areas within tumors are nutrient-rich, providing ample resources for bacterial growth and reproduction [61]. Furthermore, the abnormal structure of blood vessels associated with tumor growth, including tortuous, elongated, or abnormally dilated vessels, leads to a disorganized vascular system. The microstructure of these blood vessels often includes discontinuous endothelial cells and a lack of pericyte coverage, which may facilitate the entry of circulating bacteria into tumor tissue [62, 63]. The immunosuppressive nature of the tumor microenvironment (TME) creates an immune-privileged site, allowing bacteria to accumulate within the tumor [32, 64].

Bacteria may target tumors through various mechanisms, including chemoattractants, signaling molecules released by dying tumor cells, or the hypoxic environment within the TME. Parthenogenetic anaerobic bacteria such as Salmonella, Pseudomonas, and Escherichia coli can sense high nutrient densities within or around the tumor through chemoreceptors, suggesting a strong attraction of bacteria towards the nutrient rich TME [65]. Studies have also shown that Escherichia coli preferentially colonize lung cancer cells that secrete various signaling molecules [66]. Bacterial motility is a crucial factor enabling their deeper penetration into tumor tissue, contrasting with the inherent passive distribution and limited penetration of chemotherapeutic drugs. Bacteria, as living organisms, possess the ability to reproduce through active metabolism and acquire energy from their surroundings, resulting in sustained and effective expression and transport capabilities. Theoretically, after systemic administration, bacteria can utilize their motility to actively exit the vascular system and preferentially migrate towards regions within the tumor tissue that are more conducive to survival and proliferation, such as areas with higher immunosuppression or greater nutrient availability. Studies have shown that Salmonella begins accumulating in colonies within tumors as early as 3 days post-systemic injection and spreads throughout the tumor tissue region [67].

In essence, bacteria exhibit a tropism towards the hypoxic, nutrient-rich, and immunosuppressive TME, endowing them with an inherent tumor-targeting property. Upon successful targeting and entry into the tumor, bacteria can rapidly replicate. While further research is needed to fully elucidate the mechanisms involved, it is undeniable that many therapeutic bacteria can penetrate tumors, presenting immense potential in cancer treatment [68] .

Table 1 Bacterium types for antitumor therapy

Bacteria	Nanomaterial	Efficacy	Ref	
Escherichia coli	Carbon nitride NPs	Photoinducing in situ generation of cytotoxicspecies.	[57]	
PD1 antibody and SARS-CoV-2 spike 1 protein link to PDA nanoparticles	Increasing proliferation of CTL in DLNs and tumor tissue.	[69]	
ICG and PDA nanoparticles	Achieving homogeneous imaging signals and enhancing tumor regression.	[70]	
DOX and superparamagnetic iron oxide NPs-loaded erythrocyte	Deliver cargoes to specific regions locally.	[71]	
Polymeric pro-micelles	On-demand release of two drugs.	[72]	
OVA antigen and α-PD-1 antibody loaded PDA nanoparticles	Providing a versatile platform to prepare multimodal and long-acting therapeutics for cancer immunotherapy.	[73]	
Fe3O4 NPs	Realizing a selfsupplied therapeutic Fenton-like reaction without additional H2O2 provision.	[74]	
PDA/Ce6 nanoparticles	Exhibits efficient antitumor effect in vitro and in vivo.	[75]	
Conjugated polymer nanoparticles	Applying for cell imaging and optical barcoding.	[76]	
Photosensitizer nanoparticles	Achieving better cancer cell imaging and effectively light-mediated cancer killing.	[77]	
Liposomal formulation

encapsulating DOX and ICG

	Colonizing tumor spheroids under magnetic fields for on-demand release of the drug molecules by near-infrared stimulus.	[78]	
Au NPs	Enabling the conjugation of bacterial surfaces with diverse metal-rich nanoparticles.	[79]	
Salmonella	PLGA nanoparticles	Enhancing nanoparticle retention and distribution in solid tumors by up to a remarkable 100-fold.	[56]	
	ICG-loaded nanoparticles	Exhibiting a highly efficient photothermal killing ability for eradicating tumor without relapse.	[58]	
	Nanoparticles self-assembled from cationic polymers and plasmid DNA	Successful inhibition of tumor growth was also achieved by efficient oral delivery of VEGFR2.	[80]	
	PDA NPs	Enhance the antitumor efficacy toward malignant melanoma.	[81]	
	DOX loaded thermosensitive liposomes	Enriching M1 macrophage phenotype and T1 population.	[82]	
	PTX encapsulated liposomes	Showing strong tumor-targeting and killing properties.	[83]	
	Liposomes	Enhanced drug delivery.	[84]	
	CaCO3 shell	Achieving remarkable efficacy against both primary and metastatic tumors.	[85]	
	MnO2 nanoparticles	Modulating the immunosuppressive tumor microenvironment and triggering immune responses.	[86]	
Clostridium	Branched Au NPs	Therapyefficient CT image guided bacteriolytic tumor therapy.	[87]	
	Upconversion nanorods and Au nanorods	Improving tumors Imaging and Photothermal Therapy.	[88]	
Magnetococcus	SN-38 loaded liposomes	Improving the therapeutic index of various nanocarriers in tumor hypoxic regions.	[89]	
	Nanoliposomes	Penetrating hypoxic regions of tumors currently unattainable with conventional cancer drugs and delivering active substances to solid tumors.	[90]	
	Gold Nanoparticles	Promoting the uptake of antigens and adjuvants by APCs to arouse strong immune responses against cancer.	[91]	
Bifidobacterium	DOX-loaded bovine serum albumin nanoparticles	Enhancing the efficacy of chemotherapy.	[92]	
	MCDP nanoparticles	Achieving synergistic chemotherapy and CDT against solid tumors.	[93]	
	PDA- coated PTX nanoparticles	Enhancing the efficacy of chemotherapy.	[94]	
	The bacterial antibody decorated nano-drug missile	Promoting tumor cell apoptosis and significantly inhibiting tumor growth.	[95]	
	DOX-loaded CaP/SiO2 nanoparticles	Prolonging the survival rate and significantly inhibited the tumor progression and metastasis.	[96]	
	PLGA nanoparticles	Giving stronger imaging, longer retention period and more effective tumor therapy.	[97]	
Lactobacillus	Lactate oxidase -and prodrug tirapazamine -coloaded liposomes	Inducing strong anticancer immunity.	[98]	
	Zeolitic imidazole framework-67 nanoparticles	Leading to pyroptotic cell death and strong antitumor immunity.	[99]	
	SN-38 prodrugs	Leading to bacterial colonization in NPC tumors and a 67% inhibition in tumor growth, enhancing the efficacy of SN-38 by 54%.	[100]	
Shewanella	Zeolitic imidazole

frameworks-90 encapsulating photosensitizer methylene blue

	Finding great potential to overcome the challenges of tumor targeting and tumor heat tolerance in PTT.	[101]	
	FeS nanoparticles	This work presents a cascade bioreactor based on S. oneidensis MR-1, which is promising for enhanced CDT and immunotherapy.	[102]	
Listeria	Plasmid DNA conjugated nanoparticles	Delivering cargos of nucleic acid-based model drugs, plasmid DNAs for firefly luciferase and SEAP enzymes into multiple organs of live mice.	[103]	

Synthesis methods of bacterial-nanomaterial hybrids

Studies have demonstrated that certain anaerobic bacteria possess anaerobic targeting capabilities, allowing them to actively target and colonize hypoxic tumor microenvironments [104]. In recent years, nanotechnology has significantly advanced the application of bacteria for cancer treatment. Researchers have combined bacteria with nanomaterials to create bacterial-nanomaterial hybrids, enabling bacteria to deliver nanodrugs to tumor sites and thereby enhancing the tumor-targeting capability of the drugs. These bacterial-nanomaterial hybrids leverage the tumor-targeting abilities of bacteria alongside the advantages of nanodrugs [92]. The synthesis of bacterial-nanomaterial hybrids can be achieved through various strategies, including chemical bonding, electrostatic interactions, the streptavidin-biotin system, and other methods (Fig. 1). Table 2 provides a summary of these methods.

Fig. 1 Diagram of Different Methods for Connecting Bacteria and Nanomaterials. Created with BioRender.com

Table 2 Methods of bacterial-carrying therapeutic agents

Methods	Bacteria	Nanodrug	Cancer cell line	Ref	
Chemical bond	Salmonella Typhimurium YB1	ICG-loaded nanoparticles	MB49	[58]	
Escherichia coli MG1655	Fe3O4 NPs	CT26	[74]	
Magnetococcus marinus MC-1	SN-38 loaded liposomes	HCT116	[89]	
Magnetococcus marinus MC-1	Nanoliposomes	Colo205	[90]	
Bifidobacterium bifidum	DOX-loaded CaP/SiO2 nanoparticles	CT26	[96]	
Bifidobacterium longum	PLGA nanoparticles	MDA-MB-231	[97]	
Lactobacillus	Lactate oxidase -and prodrug tirapazamine -coloaded liposomes	4T1	[98]	
Shewanella oneidensis MR-1	Zeolitic imidazole frameworks-90 encapsulating photosensitizer methylene blue	CT26	[101]	
Electrostatic interaction	Escherichia coli	Carbon nitride NPs	4T1	[57]	
Escherichia coli	PDA/Ce6 nanoparticles	HOS, U2OS and MG63	[75]	
Escherichia coli	Conjugated polymer

nanoparticles

	A549	[76]	
Escherichia coli	Photosensitizer

nanoparticles

	HeLa cells	[77]	
Salmonella	Nanoparticles self-assembled from cationic polymers and plasmid DNA	B16	[80]	
Clostridium novyi-NT spores	Branched Au NPs	PC3	[87]	
Magnetospirillum magneticum AMB-1	Fe3O4 magnetic nanoparticles	-	[105]	
Dopamine self-polymerisation	Escherichia coli Nissle 1917	αPD1 antibody and SARS-CoV-2 spike 1 protein link to nanoparticular PDA	CT26, B16F10	[69]	
	Escherichia coli BL21	ICG and PDA nanoparticles	4T1, CT26	[70]	
	Escherichia coli Nissle 1917	OVA antigen and α-PD-1 antibody loaded PDA nanoparticles	CT26	[73]	
	Salmonella strain VNP20009	PDA nanoparticles	B16F10	[81]	
	Bifidobacterium infantis	MCDP nanoparticles	4T1	[93]	
	Bifidobacterium infantis	PDA-coated PTX nanoparticles	A549	[94]	
	Especially E.

coli Nissle 1917

	STING agonist (MSA-2) and PDA nanoparticles	B16F10	[106]	
Streptavidin-biotin interaction	Salmonella Typhimurium VNP20009	PLGA nanoparticles	HCT-116, U87MG and 4T1	[56]	
	Escherichia coli MG1655	DOX and superparamagnetic iron oxide NPs-loaded erythrocyte	-	[71]	
	Escherichia coli

MG1655

	Liposomal formulation

encapsulating DOX and ICG

	HT-29	[78]	
	Salmonella typhimurium YS1646	DOX loaded thermosensitive liposomes	CT26	[82]	
	Salmonella Typhimurium	PTX encapsulated liposomes	4T1	[83]	
	L.monocytogenes, Listeria	Plasmid DNA conjugated NPs	KB cells	[103]	
	The ΔppGpp S. typhimurium strain SHJ2037	Cy5.5-coated polystyrene microbeads	NIH/3T3, CT-26 and 4T1	[107]	
	Clostridium difficile CCUG 37,780	Upconversion nanorods and Au nanorods	A549	[88]	
	Bifidobacterium infantis	The bacterial antibody decorated nano-drug missile	A549	[94]	
Electroporation	Escherichia coli and Salmonella	Liposomes	4T1	[84]	
Active adsorption of proteins by bacteria	Bifidobacterium infantis	Adriamycin-loaded bovine serum albumin nanoparticles	4T1	[92]	
Tetrazine/norbornene click reaction	Escherichia coli	Polymeric pro-micelles	4T1	[72]	
Metal-peptide affinity	Escherichia coli	Au nanoparticles	-	[79]	
Biomineralize	Shewanella

oneidensis MR-1

	Palladium nanoparticles	CT26	[101]	
	Shewanella algae K3259	Gold nanoparticles	CT26	[108]	
	Salmonella typhimurium strain ΔppGpp	CaCO3 shell	B16F10	[85]	
	Salmonella typhimurium	MnO2 nanoparticles	CT26, B16F10 and 4T1	[86]	

Chemical bonding

Covalent bonding between nanomaterials and bacterial cells is a common method for conjugation. The bacterial outer membrane comprises various components, including peptidoglycan, teichoic acid, lipopolysaccharides, lipids, and proteins. These components provide diverse surface properties and functional groups such as thiols, hydroxyls, carboxyls, and amines [109]. Among these, amino, carboxyl, and thiol groups are the most prevalent functional groups used for chemical modification of the bacterial surface [110, 111]. Due to their simplicity, high efficiency, and mild reaction conditions, these groups serve as reactive sites. Amino groups can react with N-hydroxysuccinimide (NHS) esters, isocyanate-activated molecules, or unsaturated aldehydes and ketones [112]. Carboxyl groups can be activated and subsequently conjugated with amino-functionalized compounds using carbodiimide chemistry [113, 114]. Free thiol groups in cysteine side chains can covalently couple with maleimide-containing conjugates under neutral conditions, forming stable thioether bonds [112, 115, 116]. Coupling reactions typically target amino (-NH2) and carboxyl (-COOH) groups. Stable conjugation of bacteria with nanomaterials is primarily achieved through the formation of stable amide bonds between the peptidoglycan of bacterial cell walls or the lipid bilayers of bacterial membranes and the nanomaterials [117]. Therefore, by modifying nanoparticle surfaces with carboxyl or amino groups, amide bonds can be utilized to firmly attach nanoparticles to bacteria. This approach leverages the tumor-targeting ability of bacteria to transport nanodrugs to tumor sites [118]. Numerous studies have utilized amide bonds to link carboxyl groups on bacterial surfaces with amino groups on nanoparticles. For example, Wu et al. designed and prepared Cu2O@Salmonella Typhimurium ΔSt (ΔSt) (Cu2O@ΔSt), a novel microbial-nano drug, by covalently bonding polyethylene glycolated Cu2O nanoparticles’ amino groups with the carboxyl groups on the surface of engineered Salmonella Typhimurium to form amide bonds (Fig. 2A). Additionally, Wu et al. reported LOD/TPZ@Lips-LA, another novel microbial-nano drug [98]. LOD/TPZ@Lips-LA was constructed by anchoring liposomes co-loaded with lactate oxidase (LOD) and the prodrug tirapazamine (TPZ) onto the surface of Lactobacillus (LA) through an amide condensation reaction. The amino groups of the liposomes co-loaded with LOD and TPZ were bonded to the carboxyl groups of the Lactobacillus (LA). By modifying nanoparticles with carboxyl groups, they can also bind to the amino groups on the bacterial surface. For example, poly(lactic-co-glycolic acid) (PLGA), indocyanine green (ICG), and carboxyl-terminated polyethylene glycolated phospholipid (DSPE-PEG-COOH) can self-assemble to form nanoparticles with carboxylated surfaces using the ultrasound emulsification method. These nanoparticles can then react with the amino groups on the surface of Salmonella Typhimurium YB1 (YB1), forming amide bonds and resulting in the bacterium/nanoparticle hybrid (YB1-INP) [58]. Additionally, indocyanine green (ICG) can be encapsulated within human serum albumin (HSA) nanoparticles (HSA/ICG NPs) via intermolecular disulfide bonds. These nanoparticles can be attached to the surface of a natural photosynthetic cyanobacterium, Synechococcus elongatus PCC 7942 (Syne), through amide bonds, creating a biomimetic system (S/HSA/ICG) for triple therapy of metastatic breast cancer [110]. Besides amide bonds, nanoparticles can also covalently bind to bacteria via imine bonds. For instance, methylene blue (MB), a photosensitizer, can be encapsulated in zeolitic imidazolate framework-90 (ZIF-90) nanoparticles that contain surface aldehyde groups. These nanoparticles can react with the amino groups of the facultative anaerobe Shewanella oneidensis MR-1, forming imine bonds under mild conditions [101]. Bacteria and nanoparticles bound by chemical bonds can usually be carried out under physiological conditions and have strong binding forces and high loading rates. Therefore, bacteria-nanoparticle hybrids bound by chemical bonds are relatively stable and not easily dissociated. However, their high stability leads to low drug release efficiency, which often requires more reasonable material design so that the encapsulated drugs can be successfully released, thus hindering the implementation of this method.

Electrostatic interaction

The outer membranes of most bacteria exhibit a negative charge due to the abundance of phosphate and carboxyl groups on their cell membranes, typically resulting in an isoelectric point below 5 [119, 120]. Under physiological conditions, the pH is generally above the isoelectric point of bacterial cells. This negative charge allows for electrostatic interactions with various positively charged nanomaterials, such as polymers, inorganic materials, and liposomes, enabling direct decoration of the bacterial cell surface through simple co-incubation with live bacteria [121–128]. Consequently, by co-incubating positively charged nanomaterials with negatively charged bacteria, stable bacterial-nanomaterial hybrids can be obtained. Numerous studies have utilized the negatively charged bacterial surface to bind various cationic substances through electrostatic methods [57, 80, 87, 129]. Additionally, modifying the surface potential of bacteria allows for further surface decoration with anionic nanomaterials [130, 131]. For example, biocompatible poly(allylamine hydrochloride) (PAH) can be used to modify non-pathogenic Shewanella oneidensis (SO) [132], rendering the bacterial surface positively charged. This allows for the binding of MIL-101 metal-organic framework (MOF) nanoparticles loaded with the anticancer drug doxorubicin (DOX) and coated with negatively charged hyaluronic acid (HA). The DOX-loaded MIL-101 MOF nanoparticles and SO can bind through electrostatic interactions, resulting in the formation of the biohybrid system SO@MIL-101-DOX-HA (SO@MDH) (Fig. 2B). Another example involves labeling anaerobic Clostridium novyi-NT (C. novyi-NT) spores with branched gold nanoparticles (BGNP) for visualization of spore delivery to solid tumors via X-ray computed tomography (CT) following intratumoral injection [87]. Negatively charged C. novyi-NT spores were functionalized with positively charged, low molecular weight branched polyethylenimine (bPEI, 600 Da), increasing the surface charge of the spores to positive values. The synthesized BGNPs were modified with 4-mercaptobenzoic acid (4-MCBA) through ligand exchange, resulting in highly negatively charged BGNPs. Finally, the negatively charged BGNPs were electrostatically deposited onto the positively charged spore walls. In a PC3 prostate tumor mouse model, BGNP-coated spores were injected into the hypoxic center of each tumor, and intratumoral delivery was confirmed via CT. Polyethyleneimine (PEI) is a cationic polymer that can be surface-modified to form positively charged nanoparticles that adsorb onto bacterial surfaces. In the context of bacteria-mediated DNA vaccines, cationic polymers and DNA self-assembled nanoparticles are used for cancer immunotherapy [80]. Fe3O4 nanoparticles modified with amine-functionalized ligands exhibit a positive potential. The negatively charged surface of Magnetospirillum magneticum AMB-1 (AMB-1) allowed the formation of the bio-nanohybrid AMB-1@MNPs through electrostatic interactions [105]. This composite material is referred to as semi-artificial magnetotactic bacteria (SAMTB). The motion of this biohybrid can be regulated by adjusting the size and concentration of Fe3O4 nanoparticles, making it applicable for precise in vivo drug delivery. Furthermore, a research team developed a novel engineered bacterial system capable of targeting hypoxic tumor tissues and effectively mediating photodynamic therapy of these tumors. In this study, Escherichia coli was genetically modified to express catalase (CAT). Black phosphorus quantum dots (BPQD) were then combined with these catalase-expressing E. coli through electrostatic adsorption, producing the engineered E. coli/BPQD (EB) system [133]. This method of bacteria and nanomaterials being adsorbed to each other through positive and negative charges is simple to operate and has good biocompatibility. However, due to factors such as the strength of the charges and external interference, it can easily lead to low binding efficiency and low stability. Moreover, modifying the surface charge of bacteria can negatively affect bacterial activity.

Polydopamine adhesion

Polydopamine (PDA) is well-known for its two key chemical features: a high content of primary and secondary amines and a high content of catechol (3,4-dihydroxybenzene). The coexistence of these functional groups contributes to PDA’s strong interfacial adhesion properties, enabling it to attach to virtually all types of organic and inorganic material surfaces [134]. Inspired by mussel adhesive proteins, dopamine is a small molecule known for its ability to readily form stable PDA nanoparticles. These nanoparticles exhibit high adhesiveness, biocompatibility, negligible cytotoxicity, and good dispersion in aqueous solutions. These advantages have led to widespread applications of PDA in the biomedical field [135]. Numerous researchers have leveraged PDA’s adhesive properties to connect nanomaterials with bacteria, forming bacterial nanobiohybrids for antitumor therapy studies. For instance, a nanomedicine, MCDP, was synthesized by preparing a metal-organic framework (MOF) containing calcium peroxide and doxorubicin (DOX). Subsequently, a polydopamine (PDA) coating was applied to facilitate the attachment of the nanomedicine onto the surface of Bifidobacterium (Bif), resulting in a bacterial nanobiohybrid, MCDP@Bif [93]. MCDP@Bif enables precise delivery of CaO2 nanoparticles and doxorubicin (DOX) to tumor tissues for synergistic chemotherapy and chemodynamic therapy (CDT) (Fig. 2C). Polydopamine (PDA) conjugation can also be employed in immunotherapy as a linker for immunotherapeutic agents. Bacteria with surfaces decorated with mixed immunoactive nanoparticles can induce dual anticancer and antiviral immunity. αPD1 antibody and SARS-CoV-2 spike 1 (S1) protein were chosen as the immune checkpoint inhibitor and virus-specific antigen, respectively. Both αPD1 and S1 protein can be conjugated to PDA nanoparticles, which are then attached to the surface of Escherichia coli Nissle 1917 (EcN) [69]. Beyond its adhesive properties, PDA also exhibits photothermal effects. Under compatible conditions, indocyanine green and PDA nanodeposits can be applied to the surface of bioengineered bacteria expressing natural melanin for tumor photothermal therapy [70]. Additionally, researchers synthesized paclitaxel-loaded nanoparticles (PTX-NPs) using a diblock copolymer of methoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) as a carrier, with a PDA coating on the surface. These PTX-NPs were then linked to Bifidobacterium infantis, forming Bif@PDA-PTX-NPs hybrids. Upon reaching the hypoxic regions of tumor tissues, the PTX-NPs respond to the reductive tumor environment, releasing the paclitaxel and exerting its antitumor effects [94]. The conjugation of bacteria with nanomaterials via polydopamine has gained increasing popularity in recent years due to its advantages of excellent biocompatibility, ease of operation, strong adhesion, and the ability to dissociate in weakly acidic environments.

Streptavidin-biotin interaction

In addition to chemical bonds and electrostatic interactions, biotin-based bioconjugation interactions have also been employed for conjugating bacteria with various substances. Streptavidin, a protein isolated and purified from bacteria, forms a strong non-covalent interaction with biotin [136]. This non-covalent interaction has been extensively studied in bioanalysis and biomedical applications [137–139]. The streptavidin-biotin system has been utilized to conjugate bacteria with various substances, including compounds, nanoliposomes, and metal nanoparticles. One study reported the development of a biohybrid microrobot platform for targeted localization and multi-stimuli-responsive drug release within three-dimensional (3D) biological matrices. Magnetic nanoparticles (mNP) and nanoliposomes (NL) loaded with photothermal agents and chemotherapeutic drugs were integrated into Escherichia coli via non-covalent interactions. This biohybrid system was prepared by exploiting the streptavidin-biotin interaction between a biotin-expressing engineered strain of E. coli MG1655 and streptavidin-functionalized mNPs. Subsequently, biotinylated NLs were directly conjugated, forming a biotin-streptavidin-biotin system [140] (Fig. 2D). Red blood cell membranes can be combined with bacteria using the biotin-streptavidin-biotin system. Engineered motile bacteria and red blood cells form biohybrid microswimmers, containing the model anticancer drug doxorubicin (DOX) and superparamagnetic iron oxide nanoparticles (SPIONs). These microswimmers offer autonomous propulsion, untethered magnetic steering, and efficient drug encapsulation and release. DOX molecules and SPIONs were first loaded into red blood cells, which were then attached to genetically engineered E. coli MG1655 via a biotin-streptavidin-biotin complex [71]. Research has also utilized anaerobic Salmonella VNP20009 to bind with nanoparticles through streptavidin-biotin interactions. Streptavidin was modified onto PLGA nanoparticles, and biotin-treated bacterial antibodies were attached to the bacterial surface. Through the streptavidin-biotin interaction, PLGA nanoparticles and bacteria formed bacterial/nanomaterial composites (NanoBEADS). NanoBEADS can enhance the retention and distribution of nanoparticles in solid tumors by up to 100-fold [56]. Additionally, biotinylated Listeria monocytogenes monoclonal antibodies were used to attach streptavidin-coated polystyrene nanoparticles to the bacterial surface. Biotinylated GFP plasmids were then attached to the remaining streptavidin sites on the nanoparticles [103]. The biotin-streptavidin binding method is a more traditional choice. This strategy often has strong interactions and high stability, usually does not interfere with the activity of bacteria, and more importantly, has high specificity. However, it also often leads to low drug release efficiency.

Other methods

Other reported methods include the use of acid-labile linkers and antigen-antibody interactions to connect bacteria and nanoparticles [72, 95, 141]. Additionally, nanoparticles can be introduced into bacteria through incubation and electroporation methods [142]. Electroporation utilizes electric pulses to transiently increase the permeability of the cell membrane, allowing nanoparticles or other substances to enter the cell [143]. Research has successfully employed electroporation to introduce phosphatidylcholine-coated quantum dots into folate-modified short Bifidobacteria, leveraging the high-quality luminescent properties and photostability of quantum dots to significantly improve in vivo imaging and therapeutic effects on tumors [144]. Cell-penetrating peptides (CPPs) can also facilitate nanoparticle entry into cells without the need for an external electric field. CPPs possess the ability to transfer large molecules from the extracellular environment to the cytoplasm, a feature that has been utilized to deliver gold nanoparticles into bacterial cells [145]. Biomineralization, an extensively explored strategy involving the in-situ biosynthesis of nanoparticles, has emerged as a promising method for producing bacterial-nanoparticle hybrids. Biomineralization phenomena have been observed in various microorganisms. For instance, Bacillus subtilis has been reported to biomineralize gold ions into gold nanoparticles and deposit them on its cell wall surface [146]. Biomineralization serves as a detoxification mechanism for microorganisms, reducing heavy metal ions into nanoparticles. Numerous types of metal nanoparticles have been reported to be formed through biomineralization [147, 148]. Through a simple biomineralization process, a biocompatible and biodegradable calcium carbonate (CaCO3) shell was coated on the surface of Salmonella, forming SAL@CaCO3 [149].

The construction of bacteria-nanoparticle conjugates can be achieved through various methods, including chemical bonding, electrostatic interactions, and others. Each method possesses its own advantages and disadvantages. Consequently, a comprehensive consideration of both bacterial and nanomaterial modifications is crucial when designing these conjugates.

Fig. 2 (A) Schematic diagram of the construction of Cu2O@ΔSt microbiotic nanomedicine by bonding Cu2O onto the surface of ΔSt. Modified with permission [118]. (B) Synthesis of the self-driven, tumor tropism SO@MDH Biohybrid. Modified with permission [132]. (C) Schematic illustration showing the fabrication process of the biomotor MCDP@Bif. Modified with permission [93]. (D) Schematic illustration of the bacterial biohybrid microrobots, conjugated with NLs and mNPs. NLs are loaded with DOX and ICG, and both NLs and mNPs are conjugated to bacteria via biotin-streptavidin interactions. Modified with permission [140]

Bacteria-mediated nanomaterials for antitumor therapy

The application of nanotechnology in bacterial-based cancer therapy has advanced rapidly in recent years. Researchers have discovered that hybrid materials combining bacteria and nanomaterials can enhance tumor targeting. Numerous studies have integrated bacteria-nanomaterial hybrids with traditional cancer treatments, including radiotherapy, chemotherapy, immunotherapy, photothermal therapy, and photodynamic therapy, leading to effective eradication of tumor cells. We will elaborate from two perspectives: bacterial-mediated tumor monotherapy and combination therapy (Fig. 3).

Fig. 3 Diagram of Bacteria-Nanomaterial Hybrids Applied in Tumor Monotherapy and Synergistic Therapy. Created with BioRender.com

Monotherapy

Bacteria-mediated nanomaterials for monotherapy in tumor treatment include chemotherapy, radiotherapy, photothermal therapy, photodynamic therapy, chemodynamic therapy, and immunotherapy. Monotherapy only requires loading one therapeutic drug, making the system design simple and easy to implement, with fewer side effects. Simple photothermal therapy, even only used for subcutaneous tumors, has limited model selection and cannot be extended to other in situ models. However, the system is simple, more feasible for development, and conducive to large-scale production. Table 3 summarizes the research on the application of bacteria and nanomaterials for cancer monotherapy.

Table 3 Bacteria-mediated monotherapy

Bacteria-mediated therapy	Bacteria	Therapeutic payload	Tumor	Ref	
Chemotherapy	Escherichia coli

Nissle1917

	DOX and α-tocopheryl succinate	Breast cancer	[72]	
Salmonella Typhimurium	Paclitaxel-loaded liposomal microcargo	Breast cancer	[83]	
Magnetococcus marinus strain MC-1	SN-38 loaded liposomes	Colon cancer	[89]	
Bifdobacterium infantis	PTX-loaded NPs	Lung cancer	[94]	
Bifdobacterium infantis	DOX	Lung cancer	[95]	
Bifdobacterium infantis	Bovine serum albumin loading with DOX	Breast cancer	[92]	
Escherichia coli

Nissle1917

	DOX	Breast cancer	[114]	
Radiotherapy	Escherichia coli

MG1655

	Bi2S3 nanoparticles	Breast cancer	[150]	
Salmonella Typhimurium ΔppGpp	Bacterial luciferase, Lux and Cytolysin A	Colon cancer	[151]	
Listeria	32-Phosphorus	Pancreatic	[152]	
Photothermal Therapy	Salmonella Typhimurium YB1	ICG-loaded nanoparticles	Bladder cancer	[58]	
Escherichia coli BL21	PDA nanoparticles	Colon cancer

Breast cancer

	[70]	
Salmonella Typhimurium VNP20009	Polydopamine	Colon cancer	[81]	
B. breve UCC 2003 C. difficile CCUG 37,780	Gold nanoparticles	Lung cancer	[141]	
Escherichia coli MG1655	Gold nanoparticles	Breast cancer	[153]	
Escherichia coli MG1655	Gold nanoparticles	Colon cancer	[154]	
Escherichia coli DH5α	ICG-loaded nanoparticles	Glioblastoma	[155]	
Photodynamic Therapy	Escherichia coli Nissle 1917	Black phosphorus quantum dots	Breast cancer	[156]	
Immunotherapy	Salmonella	Cationic polymers and plasmid DNA	Melanoma	[80]	
	Salmonella typhimurium ΔppGpp	CaCO3 shell	Melanoma	[85]	
	Salmonella typhimurium	MnO2 nanoparticles	Colon cancer

Breast cancer

Melanoma

	[86]	
	Escherichia coli	Fe3O4@lipid nanocomposites and anti-CD47 nanobody	Colon cancer

Breast cancer

	[157]	
	engineering Salmonella	DNAzyme -functionalized MnO2 nanoparticles	Melanoma	[158]	
	Escherichia coli MG1655	Magnetic Fe3O4

nanoparticles

	Colon cancer	[159]	
Chemodynamic Therapy	Escherichia coli	Au@Pt core − shell nanozyme	Melanoma	[160]	

Chemotherapy

Chemotherapy is a primary treatment modality for metastatic cancer, as it allows drugs to circulate through the bloodstream and reach various metastatic sites, enabling systemic therapy [161]. Chemotherapy drugs target the growth and division processes of cancer cells, preventing their normal replication and ultimately leading to cell death. However, chemotherapy is often associated with severe side effects [162]. Recent studies have highlighted the potential of bacteria as carriers for chemotherapeutic drugs in cancer treatment, enabling specific targeting of both primary and metastatic tumors [163]. For example, a study reported the development of a biocompatible bacteria/nanoparticle hybrid (Bif@DOX-NPs) designed to enhance the efficacy of chemotherapy in breast cancer [92]. Bif@DOX-NPs selectively accumulated in tumors due to the hypoxic targeting ability of Bifidobacterium and the affinity of the bovine serum albumin (BSA) layer to the albumin-binding secreted protein acidic and rich in cysteine (SPARC), which is expressed on many solid tumors. This selective accumulation enhances the antitumor efficacy of the chemotherapeutic drug while reducing side effects (Fig. 4A). Notably, Bif@DOX-NPs significantly prolonged the survival of mice by over 30 days compared to the saline group.

Radiotherapy

Radiotherapy utilizes high-energy rays to irradiate the tumor area, killing tumor cells by inducing DNA damage. However, the hypoxic microenvironment within solid tumors significantly reduces the efficacy of radiotherapy [164]. Furthermore, studies have shown that radiotherapy can induce protective autophagy in tumor cells, enabling them to maintain homeostasis and continue proliferating and metastasizing [161]. The combination of bacteria and nanomaterials has the potential to improve the hypoxic conditions of tumors and synergistically enhance the effects of radiotherapy. Integrating bacteria with radiosensitizing nanomaterials can result in more pronounced therapeutic outcomes for tumor treatment. For instance, a study developed an integrated nanosystem composed of engineered bacteria (Bacillus) and Bi2S3 nanoparticles (BNPs) (Bac@BNP) to enhance radiosensitivity [150]. The engineered bacteria specifically colonize tumor sites and overexpress the cytolysin A (ClyA) protein, which modulates the cell cycle from the radiation-resistant phase to the radiation-sensitive phase. Meanwhile, the peptide-modified BNPs, serving as a radiosensitizer with high atomic (Z) elements, are released from the Bacillus surface in response to matrix metalloproteinase-2 (MMP2) present in the tumor microenvironment. Upon X-ray irradiation, the BNPs trigger intracellular reactive oxygen species (ROS) production, leading to DNA damage and increased radiosensitivity (Fig. 4B). Notably, mice in the PBS, PBS + X-ray, BNP, and Bacillus groups exhibited increasing mortality before day 30. In contrast, mice in the Bac@BNP group exhibited a 75% survival rate at day 60. In this study, Bac@BNP under X-ray irradiation significantly inhibited breast cancer in mice while reducing toxic side effects.

Immunotherapy

The advancement of cancer immunotherapy has brought new opportunities to oncology, making immune-based anticancer strategies increasingly significant [165–167]. Cancer immunotherapy harnesses the body’s own immune system to recognize and attack cancer cells, ultimately achieving therapeutic goals. In recent years, several studies have proposed methods using bacterial nanocarriers for immunomodulation [54]. Ma et al. utilized Fe3O4@liposome nanocomposites to genetically modify engineered Escherichia coli, developing magnetically manipulable bacteria targeted to tumors. Alternating magnetic fields (AMF) are an ideal signal for manipulating bacteria due to their virtually limitless tissue-penetrating capability and excellent biosafety. The study describes an AMF-manipulated tumor-homing bacteria (AMF-Bac), constructed by modifying genetically engineered E. coli BL21 attenuated strain with a Fe3O4@lipid nanocomposite. The magnetic engineered bacteria enable consistent magnetic field-controlled movement to enhance tumor targeting and improve therapeutic efficacy, achieving tumor-specific CD47 blockade and precise tumor immunotherapy [157] (Fig. 4C).

Photothermal therapy

Photothermal therapy (PTT) involves the absorption of photon energy by a photothermal agent, causing a transition from the ground state to the excited state. The excited photothermal agent returns to the ground state upon collision with surrounding molecules, releasing energy and generating heat [168]. Nanomaterials, including inorganic and polymer nanoparticles, serve as the primary photothermal agents [169, 170]. These nanomaterials can be combined with bacteria to form antitumor nano-bacterial complexes. In bacteria-mediated PTT therapy, tumor treatment exhibits high specificity. Bacteria carrying photosensitizers preferentially accumulate within solid tumors. Upon exposure to near-infrared laser, bacteria with photosensitizers demonstrate excellent efficacy in destroying cancer cells and eradicating solid tumors [171, 172]. Research has connected nano photosensitizers (indocyanine green nanoparticles, INPs) to the surface of Yersinia enterocolitica strain YB1, forming a bio/non-bio cross-linked system (YB1-INPs) for precise tumor treatment [173]. This YB1-INPS treatment strategy demonstrates specific hypoxia targeting against solid tumors, excellent photothermal conversion, and efficient fluorescence (FL) imaging properties. Under near-infrared laser irradiation (NIR), YB1-INPS exhibits a reliable, efficient photothermal ability to eradicate large solid tumors without recurrence (Fig. 4D). Additionally, researchers have exploited the advantages of using Salmonella VNP20009 biotherapy in combination with dopamine-mediated photothermal therapy to enhance the antitumor efficacy against malignant melanoma [92]. VNP20009 is coated with dopamine through oxidation and self-polymerization and then injected intravenously into tumor-bearing mice. The dopamine-coated VNP20009 targets the hypoxic regions of solid tumors, and upon near-infrared laser irradiation, the tumor heats up due to the presence of dopamine. This combined approach eliminates tumors with a single injection and laser irradiation, with no recurrence or metastasis.

Photodynamic therapy

Photodynamic therapy (PDT) utilizes photosensitizers, which, upon activation, generate cytotoxic reactive oxygen species (ROS), inducing apoptosis, necrosis, and autophagy in tumor cells [174]. While extensively researched as a non-invasive treatment for tumors, PDT is limited by the drawbacks of photosensitizers, including their short half-life, low solubility, and poor stability [175]. Precise delivery of sufficient photosensitizers to the tumor site remains a significant challenge [176]. Numerous studies have explored the use of nano-bacterial biohybrids for delivering photosensitizers for PDT [177]. Ding et al. developed a novel engineered bacterial system capable of targeting hypoxic tumor tissues and effectively mediating PDT for these tumors. Escherichia coli was genetically modified to express peroxidase, and black phosphorus quantum dots (BPQDs) were attached to the bacterial surface via electrostatic adsorption, generating the engineered E. coli/BPQD (EB) system [156]. Laser irradiation at 660 nm drove EB to generate ROS and disrupt the bacterial cell membrane, leading to the release of catalase, followed by its degradation to produce oxygen. Increased oxygen levels alleviate intratumoral hypoxia, thereby enhancing BPQD-mediated PDT (Fig. 4E).

Chemodynamic therapy

Chemodynamic therapy (CDT) disrupts cancer cells by converting hydrogen peroxide and superoxide in the tumor microenvironment (TME) into reactive oxygen species (ROS). However, its antitumor efficacy is limited by tumor-targeting capability. Moreover, high levels of ROS can promote the exposure of tumor-associated antigens, facilitating the engulfment of dead cells and fragments by antigen-presenting cells (APCs), thereby further eliciting a systemic immune response [27]. In recent years, bacteria integrated with functional nanoparticles have achieved precise antitumor effects through therapeutic reactions, especially Fenton-like reactions [178]. The strategy of bacteria-mediated Fenton-like reactions for tumor therapy primarily utilizes genetic engineering techniques to introduce genes encoding catalase and iron reductase into microbial cells, enabling them to produce hydrogen peroxide and ferrous ions. In Fenton-like reactions, hydrogen dioxide (H2O2) can be converted into highly reactive hydroxyl radicals (•OH) with the presence of metal catalysts [179]. As a kind of the reactive oxygen species (ROS), hydroxyl radical is of highly oxidative activity towards organic molecules and induces severe oxidative damage of tumor cells. Researchers developed an integrative bioreactor based on engineered bacteria for tumor therapy via Fenton-like reaction with localized H2O2 generation. Nonpathogenic bacterium Escherichia coli MG1655 (Ec) was engineered with respiratory chain enzyme II (NDH-2) overexpression (Ec-pE). Amino-functionalized magnetic Fe3O4 nanoparticles (MNP) were modified onto the engineered bacteria via amide bonds, constructing a Fenton-like bioreactor (Ec-pE@MNP) [159]. Under the anaerobic targeting of bacteria and the influence of an external magnetic field, Ec-pE carrying MNP reaches the tumor microenvironment with abundant spontaneous H2O2 production, generating many hydroxyl radicals to kill tumor cells (Fig. 4F).

Fig. 4 (A) Schematic diagram of the antitumor process of bacterial nanohybrids. Modified with permission [92]. (B) When self-targeted to tumor sites, the bacteria-based nanosystem could secrete ClyA protein to arrest the cell cycle to the radiosensitive phase and release BNP to realize radiotherapy sensitivity by ROS generation and DNA damage. Modified with permission [150]. (C) Illustration of potential immune responses induced by AMF-Bac. Modified with permission [157]. (D) YB1-INPs with hypoxia-targeting and photothermal-assisted bioaccumulation for tumor penetrative therapy. Modified with permission [173]. (E) Schematic illustration of a novel engineered bacterium/black phosphorus quantum dot hybrid system for hypoxic tumor targeting and efficient photodynamic therapy. Modified with permission [156]. (F) The scheme of bacteria-based Fenton-like bioreactor and its chemodynamic therapy process for antitumor therapy. Modified with permission [159]

Synergistic therapy

Given the high rates of metastasis, recurrence, individual variability, and low survival rates associated with cancer, combination therapy is particularly important and urgent [180]. Extensive research has led to the engineering of various bacterial cells as carriers for delivering chemotherapeutic drugs, plasmids, proteins, and other composite nanomedicines for tumor treatmentt [89, 181–183]. These composite nanosystems endow bacterial cells with multiple therapeutic functions, enabling multidirectional treatment approaches such as Fenton-like catalytic therapy [184], photothermal therapy [185] and biotherapy [186]. Bacteria-mediated nanomaterials for the synergistic treatment of tumors have also been extensively studied preclinically. Synergistic therapy, which employs multiple treatment methods simultaneously to combat tumors, achieves comprehensive tumor killing and exhibits enhanced therapeutic efficacy. Table 4 summarizes the research on bacteria-mediated synergistic therapy for tumor treatment.

Table 4 Bacteria-mediated synergistic therapy

Bacteria-mediated therapy	Bacteria	Therapeutic payload	Tumor	Ref	
Chemo-Chemodynamic Therapy	Bifidobacterium infantis	MCDP nanoparticles	Breast cancer	[93]	
Chemo-Chemodynamic-Immunotherapy	Escherichia coli	DOX	Breast cancer	[187]	
Chemo-Immunotherapy	Engineered

Bifidobacterium

	DOX-loaded CaP/SiO2 nanoparticles	Melanoma	[96]	
Salmonella typhimurium	DOX and temperature sensitive liposomes	Colon cancer	[188]	
Escherichia coli 1917	Autophagy inhibitor hydroxychloroquine and DOX	Pancreatic	[189]	
Photothermal-Photodynamic Therapy	Synechococcus 7942	Au-Ce6	Breast cancer	[190]	
Escherichia coli DH5α	PDA nanoparticles	Osteosarcoma	[191]	
Shewanella oneidensis MR-1	Palladium nanoparticles	Colon cancer	[192]	
Photothermal-Immunotherapy	Escherichia coli Nissle 1917	PDA nanoparticles	Colon cancer	[73]	
Escherichia coli Nissle 1917	The STING agonist and PDA nanoparticles	Melanoma	[106]	
Bifidobacterium

NBRC100015

	ICG-loaded nanoparticles	Colon cancer	[193]	
Salmonella Typhimurium VNP20009	Heptamethine cyanine dyes NHS–N782 and JQ-1	Melanoma	[194]	
Purple photosynthetic bacteria	PEG derivatives	Colon cancer	[195]	
Escherichia coli Nissle 1917	CRISPR-Cas9 plasmid-loaded

liposomes

	Breast cancer	[196]	
Photothermal-Chemotherapy	Salmonella Typhimurium

Escherichia coli MG1655

	DOX and ICG	Colorectal cancer	[78]	
	Escherichia coli Nissle 1917	CA-Dox-Hyd-SH/AuNRs complexes	Breast cancer	[197]	
Photothermal-Chemo-Chemodynamic Therapy	Escherichia coli MG 1655	Pentabromopillar arenes and cisplatin derivatives loaded TMP	Breast cancer	[198]	
Photothermal-Radiotherapy	Escherichia coli	Black phosphorus quantum dot	Colorectal cancer	[199]	
Photodynamic-Immunotherapy	Escherichia coli Nissle 1917	Iridium (III) photosensitizer	Breast cancer	[200]	
Photodynamic-Sonodynamic Therapy	Bifidobacterium

CGMCC1.2212

	Ce6 nanoparticles	Laryngeal cancer	[201]	
Radiotherapy-Immunotherapy	Salmonella Typhimurium VNP20009	Gold-platinum bimetallic nanozyme	Melanoma	[202]	
Chemodynamic-immunotherapy	Lactobacillus rhamnosus GG	Zeolitic imidazole framework-67	Breast cancer	[203]	

Photothermal therapy-based synergistic therapies

Photothermal therapy (PTT), a non-invasive treatment method, offers precise spatial and temporal control in antitumor therapy [204]. PTT converts light into heat energy through photothermal agents under specific wavelengths of near-infrared irradiation, killing tumor cells in an oxygen-independent manner. While both PDT and PTT induce cell death by generating free radicals, each has inherent limitations, making it difficult to achieve sufficient therapeutic effects with a single modality. However, the combined use of PTT and PDT not only retains the advantages of low toxicity and minimal side effects associated with phototherapy but also produces additive or even synergistic therapeutic effects, thereby enhancing efficacy and reducing side effects [205–208]. PTT can enhance immune activation, and combining PTT with immunotherapy can yield potent antitumor effects. For instance, tumor-specific antigens (OVA) and checkpoint blockade α-PD-1 antibodies can be in situ precipitated with polydopamine (PDA) to form PDA nanoparticles, which are then conjugated onto the surface of Escherichia coli (EcN). PDA exerts a photothermal effect, inducing the repolarization of M2 macrophages to M1 macrophages. The attached OVA promotes the maturation of dendritic cells (DCs), while α-PD-1 can induce the activation of cytotoxic T lymphocytes [73] (Fig. 5A). Combining chemotherapy with PTT can increase the sensitivity of tumor cells to chemotherapeutic drugs and enhance drug penetration into deeper tumor regions [204, 209]. The facultative anaerobic bacterium Escherichia coli Nissle 1917 (EcN) was functionalized to form a self-propelled microrobot, actively delivering chemotherapeutic drugs and photosensitizers to the deep hypoxic regions of tumors [197]. Doxorubicin (Dox) and gold nanorods (AuNRs) were conjugated onto the surface of EcN. Cellular co-localization of EcN-Dox-Au conjugates in MCF-7 cells was observed using CLSM. The nuclei appeared red fluorescence of Dox, and the fluorescence signals enhanced with the increase of co-incubation time, demonstrating that the conjugates could be internalized into nuclei and exert antitumor efficacy. Upon near-infrared laser irradiation near the tumor, the AuNRs converted light into heat, significantly enhancing the permeability of tumor cell membranes and increasing the penetration of both Dox and EcN, thus achieving an optimized synergistic effect of PTT and chemotherapy (Fig. 5B). Additionally, bacterial-nanomaterial hybrids can be employed for a combinatorial approach integrating chemotherapy, PTT, and CDT. A “Trojan nanobacteria hybrid,” comprising facultative anaerobic Escherichia coli MG 1655 and prodrug based HINCs (highly integrated nanocapsules), has been successfully constructed. The hybrid, termed E. coli@HINCs (HINE-Hybrid), utilizes HINCs, which are covalently cross-linked through pillararene derivatives and cisplatin prodrug linkers. These HINCs can be endocytosed and cleaved to release therapeutic agents. Under near-infrared (NIR) light irradiation (808 nm), HINCs significantly increase the system’s temperature, which further leads to the efficient production of reactive oxygen species (ROS). Moreover, in both in vitro and in vivo studies, HINE-Hybrid demonstrates significant antitumor effects and promotes immune cell infiltration and antitumor cytokine expression within the tumor microenvironment (TME) [198]. Additionally, bacterial-mediated PTT combined with radiotherapy has also been reported. A hybrid system of black phosphorus quantum dots (BPQD) and Escherichia coli (E. coli) (BE) has been developed. BPQD can directly enhance X-ray-mediated tumor radiosensitization [199], achieving significant radiotherapy efficacy at lower radiation doses. This system effectively destroys hypoxic tumor tissues, thereby inhibiting tumor growth (Fig. 5C).

Nanoparticles encapsulating the photosensitizer Ce6 and Au NPs (Au-Ce6) were conjugated to the native photosynthetic bacterium Synechococcus elongatus PCC 7942 (Syne) [190]. The engineered bacteria loaded with Au-Ce6 (Bac@AuCe6) retained the photosynthetic characteristics and tumor-targeting abilities of Syne. When a 660 nm laser irradiated the tumor site, the photosynthetic autotrophic Syne continuously released photosynthetic O2, which was immediately activated into 1O2 by the loaded photosensitizer. Subsequently, 808 nm laser irradiation was applied for PTT to further enhance tumor cytotoxicity (Fig. 5D).

Fig. 5 (A) Decorated bacteria-mediated reversal of the tumor immunosuppressive microenvironment via repolarization of TAMs, maturation of dendritic cells, and activation of cytotoxic T lymphocytes. Modified with permission [73]. (B) Schematic illustration of the developed EcN-Dox-Au microrobots for synergistic photothermal-chemotherapy and immunomodulatory effect of breast tumor. Modified with permission [197]. (C) Schematic illustration of BPQDs/bacteria system that synergistically facilitates PTT against hypoxic tumors and complementary low-dose radiotherapy. Modified with permission [199]. (D) Synthesis of Bac@Au-Ce6 and schematic diagram of PDT and PTT tumor therapy in vivo. Modified with permission [190]

Chemotherapy-based synergistic therapies

The clinical efficacy of chemotherapeutic drugs is often compromised due to poor drug selectivity, off-target effects, and drug resistance. Bacterial vectors can deliver chemotherapeutic drugs to deeper tumor regions [49, 50], and can be combined with other therapeutic modalities to enhance antitumor effects. Bacteria-mediated synergistic chemotherapy and CDT have demonstrated promising antitumor efficacy. For example, by functionalizing MCDP nanoparticles containing calcium peroxide (CaO2) and doxorubicin (DOX) onto polydopamine-coated metal-organic frameworks (MOFs), synergistic chemotherapy and chemodynamic therapy can be achieved with anaerobic Bifidobacterium infantis (Bif) [93]. 4T1 cells readily took up MIL + DOX + PDA (MDP) and MCDP NPs compared to free DOX, similar uptake was observed in A549 and CT26 cells. This hybrid material, composed of MIL framework + CaO2 + DOX + polydopamine (MCDP)@Bif, leverages the innate targeting ability of Bif to actively home in on the hypoxic regions of solid tumors. In the acidic tumor microenvironment (TME), MCDP generates hydroxyl radicals through an enhanced Fenton-like reaction between Fe2+ and the hydrogen peroxide produced by CaO2. The disruption of Ca2+ homeostasis and the resulting mitochondrial Ca2+ overload induce apoptosis and enhance oxidative stress, thereby promoting tumor cell death (Fig. 6A). Studies have also explored the use of anaerobic bacteria to mediate the synergistic effects of chemotherapy and immunotherapy. Probiotic Bifidobacterium bifidum (Bi) combined with DOX-loaded CaP/SiO2 nanoparticles (DNPs@Bi) has been utilized for tumor treatment. Studies have also explored the use of anaerobic bacteria to mediate the synergistic effects of chemotherapy and immunotherapy. Probiotic Bifidobacterium bifidum (Bi) combined with DOX-loaded CaP/SiO2 nanoparticles (DNPs@Bi) has been utilized for tumor treatment [96]. DNPs@Bi was able to enhance the cellular uptake. The DNPs@Bi system releases DOX to exert chemotherapeutic effects and induce immunogenic cell death (ICD). Furthermore, DNPs@Bi stimulates the maturation of dendritic cells (DCs) and the infiltration of cytotoxic T lymphocytes (Fig. 6B). Additionally, the integration of the chemotherapeutic drug doxorubicin (DOX) onto the surface of non-pathogenic Escherichia coli (E. coli) with high expression of glucose dehydrogenase (GDH) has been employed to enhance its antitumor efficacy. The nicotinamide adenine dinucleotide phosphate (NADPH) produced by E. coli facilitates the generation of toxic reactive oxygen species (ROS) within tumors. These ROS are subsequently catalyzed by NADPH oxidase activated by DOX. Importantly, the hybrid bacteria augment the systemic antitumor immune response, leading to effective tumor eradication [187].

Photodynamic therapy-based synergistic treatment

The tumor microenvironment (TME) is typically characterized by significant hypoxia, with partial oxygen pressure (pO2) below 20 mmHg [210–215]. This local hypoxia severely impedes the effectiveness of cancer treatments, particularly photodynamic therapy (PDT) [216–219]. Anaerobic bacteria have excellent tumor-targeting capabilities, and attaching photosensitizers to bacteria can enhance the efficacy of photodynamic therapy (PDT). For example, iridium(III) photosensitizers covalently labeled onto the surface of genetically engineered bacteria (Ir-HEcN) selectively target and penetrate deep into tumor tissues [200](Fig. 6C). Under irradiation, Ir-HEcN can induce tumor cell pyroptosis and immunogenic cell death, leading to the regression of solid tumors through the combination of PDT and immunotherapy. Additionally, the combination of photodynamic therapy (PDT) and sonodynamic therapy (SDT) can achieve superior antitumor effects. Chlorin e6 (Ce6) nanoparticles can be incorporated into bifidobacteria. Under laser or ultrasound irradiation, Ce6 generates reactive oxygen species (ROS) to kill cancer cells [201] (Fig. 6D).

Fig. 6 (A) Schematic illustration showing antitumor mechanism of the biomotor MCDP@Bif. Modified with permission [93]. (B) Bifidobacterium bifidum (Bi) was covalently modified with DOX-loaded CaP/SiO2 nanoparticles (DNPs@Bi) for tumor Therapy. Modified with permission [96]. (C) Schematic illustration of the elimination of solid tumors by enhanced photodynamic immunotherapy. The injected photosensitizer-bacteria hybrid induces photodynamic therapy at tumor tissues under irradiation and evokes innate and adaptive immune responses, thereby leading to the final tumor regression. Modified with permission [200]. (D) Combination of laser and US exposure exerted a synergistic effect on ROS generation of Ce6–B. bifidum–anti-DR5 Ab (a) and Combined 671 nm laser and US targeted therapy (b). Modified with permission [201]

Others

In addition to the common bacterial-mediated combination therapies, bacterial vectors can activate the immune system or synergize with other treatments such as immunotherapy, chemotherapy, or radiotherapy to enhance antitumor effects [55, 220–226]. For instance, engineered Salmonella typhimurium strains secreting Vibrio vulnificus flagellin B (SLpFlaB) have been used to activate immune responses and, in combination with radiotherapy, enhance the treatment of intracranial sarcomas [227, 228]. Moreover, another study designed a bacterial vector coated with gold-platinum bimetallic nanozymes (Au-Pt@VNP20009, APV). This system leverages the intense tumor inflammatory response induced by low-dose X-rays, significantly enhancing the tumor-targeting delivery capacity of CD11b + immune cells hitchhiking on APV. This approach effectively alleviates tumor hypoxia and immune suppression, thereby inhibiting tumor growth and metastasis [229]. Synergistic therapy has better therapeutic efficacy. It uses multiple treatment methods simultaneously to fight tumors, achieving comprehensive tumor killing. Especially after combining with immunotherapy, the recurrence rate is lower in the long term. However, the system synthesis is composed of two or more therapeutic agents, leading to high complexity and potentially increased side effects compared to monotherapy. Drug development becomes more difficult and costly.

Challenges and outlook

Tumor-targeting bacteria can specifically penetrate primary tumors and metastases throughout the body and proliferate within necrotic areas [230]. This unique proliferation mechanism effectively overcomes the limitations of current clinical cancer treatments, such as chemotherapy, molecular targeted therapy, cell therapy, and antibody therapy, which cannot penetrate the interior of tumors, and radiotherapy, surgery, and other physical therapies that cannot target potential metastatic sites. However, clinical trial results have shown that bacterial monotherapy has not yet achieved significant antitumor effects [33, 231]. This is primarily because the cytotoxicity of tumor-targeting engineered bacteria is insufficient to eliminate tumor cells, and the secreted therapeutic agents cannot diffuse throughout the entire solid tumor. Additionally, the proliferation of some bacteria may promote tumor growth and metastasis, posing significant challenges for clinical application [232]. Therefore, combining bacterial targeted therapy with the advantages of existing clinical treatments is crucial for its ultimate clinical application. The application of bacteria-nanoparticle hybrids has been shown to successfully promote tumor regression and prolong survival in mouse models. Although many published studies on bacteria-based biotherapy have shown promising results in experimental models, the use of tumor-targeting bacteria in clinical practice as therapeutic drugs still faces significant hurdles. There are still some challenges that need to be addressed.

First, potential risks associated with bacteria must be carefully considered. Given that these conjugates contain live bacterial cells, addressing biosafety concerns is paramount. Rapid introduction of a large number of bacterial cells into the human body can trigger a strong immune response [233, 234]. Researchers have proposed several solutions to address the safety concerns of using bacteria as bioactive drug carriers. Firstly, it is recommended to use biocompatible probiotics or non-pathogenic bacteria for treatment. E coli Nissle 1917, a non-pathogenic intestinal probiotic, has been used to treat gastrointestinal diseases [235, 236]. Bifidobacterium is also known for its oral probiotic use. Second, reducing the pathogenicity of bacteria by deleting virulence-related genes can alleviate immune responses. For example, genetically engineered Salmonella strains lacking ppGpp genes elicit weaker immune responses and have been applied in antitumor therapy [237]. Additionally, attenuation strategies can be employed to reduce the virulence of pathogenic bacteria. These approaches can enhance the safety and efficacy of bacterial-nanoparticle conjugates, facilitating their clinical development. Second, the binding stability of nanoparticles and bacteria during in vivo transport needs improvement, and conducting clinical trials also presents significant difficulties. Furthermore, limited drug loading efficiency is another challenge hindering the anti-cancer efficacy of bacteria. Besides further optimizing the preparation methods, genetically modifying bacteria to produce anti-cancer drugs may enhance the therapeutic effect. Finally, the production process for live bacteria is more complex than that for small molecule anti-cancer drugs. Unlike small molecules or other non-active clinical drugs, live therapeutic bacteria cannot be sterilized by filtration or heat treatment, which would be the greatest challenge for producing products that pass Good Manufacturing Practice (GMP) grade testing. Traditional sterility testing standards will no longer apply. Therefore, real-time supervision, production, purification, and harvesting of live bacteria under strict aseptic procedures are practical methods to ensure the quality of the final product. Bacterial seed banks and storage systems should also be further optimized. Finally, the potential environmental impact when live bacteria can be used in a clinical setting is another issue that needs to be carefully addressed.

Bacteria can deliver a variety of drugs, amino acids, and proteins. Their excellent tumor-targeting properties make them play a crucial role in cancer treatment. It is noteworthy, however, that there are also some issues that need to be addressed in future work in bacterial-mediated synergistic cancer therapy. To facilitate the clinical application of bacterial synergistic therapy, more resources need to be invested in researching large-scale production, sterilization techniques, management plans, production equipment, storage, and transportation methods. Tumor therapy with bacteria-mediated nanomaterials also requires further research, which will provide a solid theoretical basis and new development directions for promoting tumor treatment. Although this novel drug delivery system requires improvement, bacteria-nanoparticle conjugates have demonstrated their potential in enhancing nanomaterial targeted delivery through bacterial tumor colonization. This innovative therapeutic approach has shown promising preliminary results. Since the initial attempts to use bacteria for tumor treatment, the concept of bacterial biotherapy and its effectiveness as a drug delivery system for various diseases have been widely recognized. The powerful tumor colonization ability of bacteria makes them ideal carriers for tumor-targeted drug delivery. By combining the antitumor advantages of nanomedicine with the targeting ability of bacteria, this novel delivery system can specifically enhance tumor therapeutic efficacy while significantly reducing side effects. Combining bacteria-nanoparticle conjugates with traditional or novel antitumor therapies may represent a new direction for future cancer treatment. This approach holds great potential and broad prospects for development in the biomedical field, especially in oncology.

Conclusions

This review summarizes the mechanisms potentially involved in bacterial targeting of tumors, as well as the construction strategies for bacteria-nanoparticle conjugates and their applications in antitumor therapy. Bacteria used for antitumor therapy could target tumors and colonize hypoxic tumor regions, making them ideal nanocarriers for delivering drugs to tumor areas. Therefore, constructing novel drug delivery systems by combining bacteria with nanomaterials occupies an important position in antitumor therapy research. Bacteria are attracted to the TME, which is characterized by hypoxia, nutrient richness, and immunosuppression. Some chemoattractants, as well as the active movement ability of bacteria, are also key factors in enabling bacteria to target tumor sites. Bacterial targeting offers higher targeting efficiency and penetration compared to traditional ligand-modified targeting. Additionally, bacteria can carry a wide variety of therapeutic agents, such as anticancer drugs, immunomodulators, and gene therapy vectors. Bacteria-nanoparticles can be applied in various cancer treatment modalities. In conclusion, this anti-cancer method utilizes the active targeting ability of bacteria and the high efficiency of nanomaterials in killing cancer cells, achieving enhanced targeting effects in tumor treatment. Although bacteria-based therapies are still in their infancy, they have immense potential. The combination of bacterial therapy with other treatments to generate effective cancer therapies remains a topic worthy of further research. One of the main focuses currently is to effectively combine bacteria-based therapies with nanomedicine. Utilizing bacterial tumor colonization can lead to the development of novel antitumor drugs for use in routine clinical applications.

Acknowledgements

Authors are thankful to all those provided support for this study. All figures have been drawn using a platform of Biorender.com.

Author contributions

Susu Xiao and Min Mu wrote the main manuscript text , Chenqian Feng prepared Figs. 1, 2, 3, 4, 5 and 6 and Shulin Pan prepared Tables 1, 2 and 3. All authors reviewed the manuscript.

Funding

None.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

We have included 4 figures (Figs. 2, 4, 5 and 6) from previously published literature with required copyright permission from the copyright owners. The graphical abstract, Scheme 1, Figs. 1 and 3 were created with Biorender.com. We have mentioned this in the manuscript with appropriate citations. All authors approved the final manuscript for the submission to this journal.

Competing interests

The authors declare no competing interests.

Abbreviations

PTT Photothermal therapy

PDT Photodynamic therapy

CDT Chemodynamic therapy

TME Tumor microenvironment

DOX Doxorubicin

PTX Paclitaxel

PLGA Poly (lactic-co-glycolic acid)

PDA Polydopamine

ICG Indocyanine green

ROS Reactive oxygen species

1O2 Singlet oxygen

NPs Nanoparticles

mNP Magnetic nanoparticles

NL Nanoliposomes

Ce6 Chlorin e6

OVA Ovalbumin

APCs Antigen-presenting cells

DCs Dendritic cells

TAMs Tumor-associated macrophages

AMF Alternating magnetic fields

BSA Bovine serum albumin

4-MCBA 4-mercaptobenzoic acid

PEI Polyethyleneimine

SPIONs Superparamagnetic iron oxide nanoparticles

NIR Near-infrared laser irradiation

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Susu Xiao and Min Mu contributed equally to this work.
==== Refs
References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer, Statistics. 2021. CA Cancer J Clin. 2021;71(1):7–33.
2. Shi J Kantoff PW Wooster R Farokhzad OC Cancer nanomedicine: progress, challenges and opportunities Nat Rev Cancer 2017 17 1 20 37 10.1038/nrc.2016.108 27834398
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.27834398 10.1038/nrc.2016.108
3. Baghban R Roshangar L Jahanban-Esfahlan R Seidi K Zare P Tumor microenvironment complexity and therapeutic implications at a glance Cell Commun Signal 2020 18 1 59 10.1186/s12964-020-0530-4 32264958
Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Zare P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59.32264958 10.1186/s12964-020-0530-4
4. Blanco E Shen H Ferrari M Principles of Nanoparticle Design for Overcoming Biological barriers to Drug Delivery Nat Biotechnol 2020 9 941 51
Blanco E, Shen H, Ferrari M. Principles of Nanoparticle Design for Overcoming Biological barriers to Drug Delivery. Nat Biotechnol. 2020;9:941–51.
5. Guo Q Jiang C Delivery strategies for macromolecular drugs in cancer therapy Acta Pharm Sin B 2020 10 6 979 86 10.1016/j.apsb.2020.01.009 32642406
Guo Q, Jiang C. Delivery strategies for macromolecular drugs in cancer therapy. Acta Pharm Sin B. 2020;10(6):979–86.32642406 10.1016/j.apsb.2020.01.009
6. Manzari M Shamay Y Kiguchi H Rosen N Scaltriti M Heller D Targeted drug delivery strategies for precision medicines Nat Rev Mater 2021 6 4 351 70 10.1038/s41578-020-00269-6 34950512
Manzari M, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller D. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351–70.34950512 10.1038/s41578-020-00269-6
7. Alqahtani MS, Alqahtani A, Syed R, Thabit A, Roni M. Novel lignin nanoparticles for oral drug delivery. J Mater Chem B. 2019;7(28).
8. Landgraf M Lahr C Kaur I Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis Biomaterials 2020 240 119791 10.1016/j.biomaterials.2020.119791 32109589
Landgraf M, Lahr C, Kaur I, et al. Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis. Biomaterials. 2020;240:119791.32109589 10.1016/j.biomaterials.2020.119791
9. Florea AM Büsselberg D Cisplatin as an Anti-tumor Drug: Cellular mechanisms of Activity, Drug Resistance and Induced Side effects Cancers 2011 3 1 1351 71 10.3390/cancers3011351 24212665
Florea AM, Büsselberg D. Cisplatin as an Anti-tumor Drug: Cellular mechanisms of Activity, Drug Resistance and Induced Side effects. Cancers. 2011;3(1):1351–71.24212665 10.3390/cancers3011351
10. Hartmann J Lipp H Toxicity of platinum compounds Expert Opin Pharmacother 2003 4 6 889 901 10.1517/14656566.4.6.889 12783586
Hartmann J, Lipp H. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889–901.12783586 10.1517/14656566.4.6.889
11. Baldo BA Pham NH Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch Cancer Metastasis Rev 2013 32 3–4 723 61 10.1007/s10555-013-9447-3 24043487
Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev. 2013;32(3–4):723–61.24043487 10.1007/s10555-013-9447-3
12. Witzigmann D Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications J Control Release 2015 200 138 57 10.1016/j.jconrel.2014.12.030 25545217
Witzigmann D. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–57.25545217 10.1016/j.jconrel.2014.12.030
13. Klein J Probing the interactions of proteins and nanoparticles Proc Natl Acad Sci U S A 2007 104 7 2029 30 10.1073/pnas.0611610104 17284585
Klein J. Probing the interactions of proteins and nanoparticles. Proc Natl Acad Sci U S A. 2007;104(7):2029–30.17284585 10.1073/pnas.0611610104
14. Jia L XinLiu HuiXia, JindongShi, XiangyangShen, Mingwu. Ultrasound-enhanced precision tumor theranostics using cell membrane-coated and pH-responsive nanoclusters assembled from ultrasmall iron oxide nanoparticles Nano Today 2021 36 1 9
Jia L, XinLiu. HuiXia, JindongShi, XiangyangShen, Mingwu. Ultrasound-enhanced precision tumor theranostics using cell membrane-coated and pH-responsive nanoclusters assembled from ultrasmall iron oxide nanoparticles. Nano Today. 2021;36(1):9.
15. Moghimi SM Szebeni J Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties Prog Lipid Res 2003 42 6 463 78 10.1016/S0163-7827(03)00033-X 14559067
Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463–78.14559067 10.1016/S0163-7827(03)00033-X
16. Feliciano CP Tsuboi K Suzuki K Kimura H Nagasaki Y Long-term bioavailability of redox nanoparticles effectively reduces organ dysfunctions and death in whole-body irradiated mice Biomaterials 2017 129 68 82 10.1016/j.biomaterials.2017.03.011 28324866
Feliciano CP, Tsuboi K, Suzuki K, Kimura H, Nagasaki Y. Long-term bioavailability of redox nanoparticles effectively reduces organ dysfunctions and death in whole-body irradiated mice. Biomaterials. 2017;129:68–82.28324866 10.1016/j.biomaterials.2017.03.011
17. B AGAA, C VP C DTLBC Tumor-targeted nanomedicines for cancer theranostics Pharmacol Res 2017 115 87 95 10.1016/j.phrs.2016.11.014 27865762
B AGAA, C VP, C DTLBC. Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res. 2017;115:87–95.27865762 10.1016/j.phrs.2016.11.014
18. van der Meel R Sulheim E Shi Y Kiessling F Mulder W Lammers T Smart cancer nanomedicine Nat Nanotechnol 2019 14 11 1007 17 10.1038/s41565-019-0567-y 31695150
van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder W, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(11):1007–17.31695150 10.1038/s41565-019-0567-y
19. Prabhakar U Maeda H Jain RK Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res 2013 73 8 2412 7 10.1158/0008-5472.CAN-12-4561 23423979
Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73(8):2412–7.23423979 10.1158/0008-5472.CAN-12-4561
20. Yetisgin AA Cetinel S Zuvin M Kosar A Kutlu O Therapeutic nanoparticles and their targeted delivery applications Molecules 2020 25 9 2193 10.3390/molecules25092193 32397080
Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193.32397080 10.3390/molecules25092193
21. Tearney GJ Fukumura D Jain RK Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging Nat Med 2009 15 10 1219 23 10.1038/nm.1971 19749772
Tearney GJ, Fukumura D, Jain RK, et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med. 2009;15(10):1219–23.19749772 10.1038/nm.1971
22. Smoody A Adayton P Zamboni WC Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response Cancer Drug Resist 2021 4 2 382 413 34796317
Smoody A, Adayton P, Zamboni WC. Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response. Cancer Drug Resist. 2021;4(2):382–413.34796317
23. Jain RK Stylianopoulos T Delivering nanomedicine to solid tumors Nat Rev Clin Oncol 2010 7 11 653 64 10.1038/nrclinonc.2010.139 20838415
Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–64.20838415 10.1038/nrclinonc.2010.139
24. Wilson WR Hay MP Targeting hypoxia in cancer therapy Nat Rev Cancer 2011 11 6 393 410 10.1038/nrc3064 21606941
Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393–410.21606941 10.1038/nrc3064
25. Becerra-Báez E Meza-Toledo S Muñoz-López P Recombinant attenuated Salmonella enterica as a delivery system of Heterologous molecules in Cancer Therapy Cancers 2022 14 17 4224 10.3390/cancers14174224 36077761
Becerra-Báez E, Meza-Toledo S, Muñoz-López P, et al. Recombinant attenuated Salmonella enterica as a delivery system of Heterologous molecules in Cancer Therapy. Cancers. 2022;14(17):4224.36077761 10.3390/cancers14174224
26. Awan BN Fatima N Riaz S Malik S Ahmad W Bacterial and liposomal vector guided Drug Delivery System via TumorMarkers Carrier Gene to treat Neoplasm J App Pharm 2015 8 1
Awan BN, Fatima N, Riaz S, Malik S, Ahmad W. Bacterial and liposomal vector guided Drug Delivery System via TumorMarkers Carrier Gene to treat Neoplasm. J App Pharm. 2015;8:1.
27. Xie Y Huang M Li D Bacteria-based nanodrug for anticancer therapy Pharmacol Res 2022 182 106282 10.1016/j.phrs.2022.106282 35662630
Xie Y, Huang M, Li D, et al. Bacteria-based nanodrug for anticancer therapy. Pharmacol Res. 2022;182:106282.35662630 10.1016/j.phrs.2022.106282
28. Jain R Normalization of Tumor vasculature: an emerging Concept in Antiangiogenic Therapy Science 2005 307 5706 58 62 10.1126/science.1104819 15637262
Jain R. Normalization of Tumor vasculature: an emerging Concept in Antiangiogenic Therapy. Science. 2005;307(5706):58–62.15637262 10.1126/science.1104819
29. Danquah MK Zhang XA Mahato RI Extravasation of polymeric nanomedicines across tumor vasculature Adv Drug Deliv Rev 2011 63 8 623 39 10.1016/j.addr.2010.11.005 21144874
Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011;63(8):623–39.21144874 10.1016/j.addr.2010.11.005
30. Forbes N Engineering the perfect (bacterial) cancer therapy Nat Rev Cancer 2010 10 11 785 94 10.1038/nrc2934 20944664
Forbes N. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010;10(11):785–94.20944664 10.1038/nrc2934
31. Yu YA Shabahang S Timiryasova TM Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins Nat Biotechnol 2004 22 3 313 20 10.1038/nbt937 14990953
Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol. 2004;22(3):313–20.14990953 10.1038/nbt937
32. Kim S Castro F Paterson Y Gravekamp C High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action Cancer Res 2009 69 14 5860 6 10.1158/0008-5472.CAN-08-4855 19584282
Kim S, Castro F, Paterson Y, Gravekamp C. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009;69(14):5860–6.19584282 10.1158/0008-5472.CAN-08-4855
33. Toso J Gill V Hwu P Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma J Clin Oncol 2002 20 1 142 52 10.1200/JCO.2002.20.1.142 11773163
Toso J, Gill V, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20(1):142–52.11773163 10.1200/JCO.2002.20.1.142
34. Charbonneau M Isabella V Li N Kurtz C Developing a new class of engineered live bacterial therapeutics to treat human diseases Nat Commun 2020 11 1 1738 10.1038/s41467-020-15508-1 32269218
Charbonneau M, Isabella V, Li N, Kurtz C. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat Commun. 2020;11(1):1738.32269218 10.1038/s41467-020-15508-1
35. Afkhami-Poostchi A Mashreghi M Iranshahi M Matin MM Use of a genetically engineered E. Coli overexpressing β-glucuronidase accompanied by glycyrrhizic acid, a natural and anti-inflammatory agent, for directed treatment of colon carcinoma in a mouse model Int J Pharm 2020 579 119159 10.1016/j.ijpharm.2020.119159 32081798
Afkhami-Poostchi A, Mashreghi M, Iranshahi M, Matin MM. Use of a genetically engineered E. Coli overexpressing β-glucuronidase accompanied by glycyrrhizic acid, a natural and anti-inflammatory agent, for directed treatment of colon carcinoma in a mouse model. Int J Pharm. 2020;579:119159.32081798 10.1016/j.ijpharm.2020.119159
36. Hayashi K Zhao M Yamauchi K Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium J Cell Biochem 2009 106 6 992 8 10.1002/jcb.22078 19199339
Hayashi K, Zhao M, Yamauchi K, et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem. 2009;106(6):992–8.19199339 10.1002/jcb.22078
37. Zheng J Nguyen V Jiang S Salmonella typhimuriumtwo-step enhanced cancer immunotherapy with engineered secreting heterologous flagellin Sci Transl Med 2017 9 376 eaak9537 10.1126/scitranslmed.aak9537 28179508
Zheng J, Nguyen V, Jiang S, et al. Salmonella typhimuriumtwo-step enhanced cancer immunotherapy with engineered secreting heterologous flagellin. Sci Transl Med. 2017;9(376):eaak9537.28179508 10.1126/scitranslmed.aak9537
38. Liu S Minton N Giaccia A Brown J Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis Gene Ther 2002 9 4 291 6 10.1038/sj.gt.3301659 11896468
Liu S, Minton N, Giaccia A, Brown J. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 2002;9(4):291–6.11896468 10.1038/sj.gt.3301659
39. Broadway K Suh S Behkam B Scharf B Optimizing the restored chemotactic behavior of anticancer agent Salmonella enterica Serovar Typhimurium VNP20009 J Biotechnol 2017 251 76 83 10.1016/j.jbiotec.2017.04.006 28433721
Broadway K, Suh S, Behkam B, Scharf B. Optimizing the restored chemotactic behavior of anticancer agent Salmonella enterica Serovar Typhimurium VNP20009. J Biotechnol. 2017;251:76–83.28433721 10.1016/j.jbiotec.2017.04.006
40. Feng X He P Zeng C Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors Oncol Lett 2021 21 2 110 10.3892/ol.2020.12371 33376543
Feng X, He P, Zeng C, et al. Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors. Oncol Lett. 2021;21(2):110.33376543 10.3892/ol.2020.12371
41. Staedtke V Roberts N Bai R Zhou S Clostridium novyi-NT in cancer therapy Genes Dis 2016 3 2 144 52 10.1016/j.gendis.2016.01.003 30258882
Staedtke V, Roberts N, Bai R, Zhou S. Clostridium novyi-NT in cancer therapy. Genes Dis. 2016;3(2):144–52.30258882 10.1016/j.gendis.2016.01.003
42. Pan Z Weiskirch L Paterson Y Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine Cancer Res 1999 59 20 5264 5249 10537307
Pan Z, Weiskirch L, Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. 1999;59(20):5264–5249.10537307
43. Parker R Plummer H Effect of histolyticus infection and toxin on transplantable mouse tumors Proc Soc Exp Biol Med 1947 66 2 461 7 10.3181/00379727-66-16124 18921791
Parker R, Plummer H. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med. 1947;66(2):461–7.18921791 10.3181/00379727-66-16124
44. Malmgren R Flanigan C Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration Cancer Res 1955 15 7 473 8 13240693
Malmgren R, Flanigan C. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 1955;15(7):473–8.13240693
45. Pawelek J Low K Bermudes D Tumor-targeted Salmonella as a novel anticancer vector Cancer Res 1997 57 20 4537 44 9377566
Pawelek J, Low K, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997;57(20):4537–44.9377566
46. Lambin P Theys J Landuyt W Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours Anaerobe 1998 4 4 183 8 10.1006/anae.1998.0161 16887640
Lambin P, Theys J, Landuyt W, et al. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe. 1998;4(4):183–8.16887640 10.1006/anae.1998.0161
47. Goto Y Iwata S Miyahara M Miyako E Discovery of Intratumoral oncolytic Bacteria toward targeted Anticancer Theranostics Adv Sci 2023 10 20 e2301679 10.1002/advs.202301679
Goto Y, Iwata S, Miyahara M, Miyako E. Discovery of Intratumoral oncolytic Bacteria toward targeted Anticancer Theranostics. Adv Sci. 2023;10(20):e2301679.10.1002/advs.202301679
48. Mostaghaci B Yasa O Zhuang J Sitti M Bioadhesive Bacterial microswimmers for targeted drug delivery in the urinary and gastrointestinal tracts Adv Sci 2017 4 6 1700058 10.1002/advs.201700058
Mostaghaci B, Yasa O, Zhuang J, Sitti M. Bioadhesive Bacterial microswimmers for targeted drug delivery in the urinary and gastrointestinal tracts. Adv Sci. 2017;4(6):1700058.10.1002/advs.201700058
49. Cronin M Morrissey D Rajendran S Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors Mol Ther 2010 18 7 1397 407 10.1038/mt.2010.59 20389288
Cronin M, Morrissey D, Rajendran S, et al. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol Ther. 2010;18(7):1397–407.20389288 10.1038/mt.2010.59
50. Fan J Li Z Liu X Zheng D Chen Y Zhang X Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration Nano Lett 2018 18 4 2373 80 10.1021/acs.nanolett.7b05323 29558152
Fan J, Li Z, Liu X, Zheng D, Chen Y, Zhang X. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration. Nano Lett. 2018;18(4):2373–80.29558152 10.1021/acs.nanolett.7b05323
51. Zhu C Ji Z Ma J Ding Z Shen J Wang Q Recent advances of nanotechnology-facilitated Bacteria-based drug and gene Delivery systems for Cancer Treatment Pharmaceutics 2021 13 7 940 10.3390/pharmaceutics13070940 34202452
Zhu C, Ji Z, Ma J, Ding Z, Shen J, Wang Q. Recent advances of nanotechnology-facilitated Bacteria-based drug and gene Delivery systems for Cancer Treatment. Pharmaceutics. 2021;13(7):940.34202452 10.3390/pharmaceutics13070940
52. Kojima M Zhang Z Nakajima M Ooe K Fukuda T Construction and evaluation of bacteria-driven liposome Sens Actuat B-Chem 2013 183 395 400 10.1016/j.snb.2013.03.127
Kojima M, Zhang Z, Nakajima M, Ooe K, Fukuda T. Construction and evaluation of bacteria-driven liposome. Sens Actuat B-Chem. 2013;183:395–400.10.1016/j.snb.2013.03.127
53. Allemailem KS Innovative approaches of Engineering Tumor-Targeting Bacteria with different therapeutic payloads to Fight Cancer: a Smart Strategy of Disease Management Int J Nanomed 2021 16 8159 84 10.2147/IJN.S338272
Allemailem KS. Innovative approaches of Engineering Tumor-Targeting Bacteria with different therapeutic payloads to Fight Cancer: a Smart Strategy of Disease Management. Int J Nanomed. 2021;16:8159–84.10.2147/IJN.S338272
54. Moreno V Baeza A Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology Pharmaceutics 2022 14 4 784 10.3390/pharmaceutics14040784 35456618
Moreno V, Baeza A. Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology. Pharmaceutics. 2022;14(4):784.35456618 10.3390/pharmaceutics14040784
55. Cao Z Liu J Bacteria and bacterial derivatives as drug carriers for cancer therapy J Control Release 2020 326 396 407 10.1016/j.jconrel.2020.07.009 32681947
Cao Z, Liu J. Bacteria and bacterial derivatives as drug carriers for cancer therapy. J Control Release. 2020;326:396–407.32681947 10.1016/j.jconrel.2020.07.009
56. Suh S Jo A Traore M Nanoscale Bacteria-Enabled Autonomous Drug Delivery System (NanoBEADS) enhances Intratumoral Transport of Nanomedicine Adv Sci 2019 6 3 1801309 10.1002/advs.201801309
Suh S, Jo A, Traore M, et al. Nanoscale Bacteria-Enabled Autonomous Drug Delivery System (NanoBEADS) enhances Intratumoral Transport of Nanomedicine. Adv Sci. 2019;6(3):1801309.10.1002/advs.201801309
57. Zheng D Chen Y Li Z Optically-controlled bacterial metabolite for cancer therapy Nat Commun 2018 9 1 1680 10.1038/s41467-018-03233-9 29700283
Zheng D, Chen Y, Li Z, et al. Optically-controlled bacterial metabolite for cancer therapy. Nat Commun. 2018;9(1):1680.29700283 10.1038/s41467-018-03233-9
58. Chen F Zang Z Chen Z Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy Biomaterials 2019 214 119226 10.1016/j.biomaterials.2019.119226 31174068
Chen F, Zang Z, Chen Z, et al. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy. Biomaterials. 2019;214:119226.31174068 10.1016/j.biomaterials.2019.119226
59. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004:4–9.
60. Pan H Zheng M Ma A Liu L Cai L Cell/Bacteria-Based bioactive materials for Cancer Immune Modulation and Precision Therapy Adv Mater 2021 33 50 e2100241 10.1002/adma.202100241 34121236
Pan H, Zheng M, Ma A, Liu L, Cai L. Cell/Bacteria-Based bioactive materials for Cancer Immune Modulation and Precision Therapy. Adv Mater. 2021;33(50):e2100241.34121236 10.1002/adma.202100241
61. Yifan X, Feng X, Xiaoxue Z et al. Microbiota in tumors: from understanding to application. Adv Sci 2022;9(21).
62. Pries A Cornelissen A Sloot A Structural adaptation and heterogeneity of normal and tumor microvascular networks PLoS Comput Biol 2009 5 5 e1000394 10.1371/journal.pcbi.1000394 19478883
Pries A, Cornelissen A, Sloot A, et al. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol. 2009;5(5):e1000394.19478883 10.1371/journal.pcbi.1000394
63. Gong X-T, Zhuang J, Chong KC et al. Far-Red Aggregation-Induced Emission Hydrogel-Reinforced Tissue Clearing for 3D Vasculature Imaging of Whole Lung and Whole Tumor. Adv Mater. n/a(n/a):2402853.
64. Céline AB, Edwin RM, Teodora IK et al. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res. 2012;72(24).
65. Jochen S, Stephanie W, Philip JH, Tobias AO, Werner G, Aladar AS. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol. 2007;297(3).
66. Rachel WK, Neil SF. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res. 2007;67(7).
67. R B A SG. J P S, B B, N S F. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther. 2011;18(7).
68. Ming Z, Meng Y, Xiao-Ming L et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A. 2005;102(3).
69. Liu Y Zhang M Wang X Dressing Bacteria with a hybrid Immunoactive Nanosurface to Elicit Dual Anticancer and antiviral immunity Adv Mater 2023 35 11 e2210949 10.1002/adma.202210949 36564893
Liu Y, Zhang M, Wang X, et al. Dressing Bacteria with a hybrid Immunoactive Nanosurface to Elicit Dual Anticancer and antiviral immunity. Adv Mater. 2023;35(11):e2210949.36564893 10.1002/adma.202210949
70. Guo H Cao Z Li J Integrating Bacteria with a Ternary combination of photosensitizers for monochromatic irradiation-mediated photoacoustic imaging-guided synergistic Photothermal Therapy ACS Nano 2023 17 5 5059 71 10.1021/acsnano.3c00032 36847803
Guo H, Cao Z, Li J, et al. Integrating Bacteria with a Ternary combination of photosensitizers for monochromatic irradiation-mediated photoacoustic imaging-guided synergistic Photothermal Therapy. ACS Nano. 2023;17(5):5059–71.36847803 10.1021/acsnano.3c00032
71. Alapan Y Yasa O Schauer O Soft erythrocyte-based bacterial microswimmers for cargo delivery Sci Robot 2018 3 17 eaar4423 10.1126/scirobotics.aar4423 33141741
Alapan Y, Yasa O, Schauer O, et al. Soft erythrocyte-based bacterial microswimmers for cargo delivery. Sci Robot. 2018;3(17):eaar4423.33141741 10.1126/scirobotics.aar4423
72. Xie S Chen M Song X Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy Acta Biomater 2018 78 198 210 10.1016/j.actbio.2018.07.041 30036720
Xie S, Chen M, Song X, et al. Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy. Acta Biomater. 2018;78:198–210.30036720 10.1016/j.actbio.2018.07.041
73. Li J Xia Q Guo H Decorating Bacteria with Triple Immune Nanoactivators generates Tumor-Resident Living Immunotherapeutics Angew Chem Int Ed Engl 2022 61 27 e202202409 10.1002/anie.202202409 35403784
Li J, Xia Q, Guo H, et al. Decorating Bacteria with Triple Immune Nanoactivators generates Tumor-Resident Living Immunotherapeutics. Angew Chem Int Ed Engl. 2022;61(27):e202202409.35403784 10.1002/anie.202202409
74. Fan Ju P, Mu, Wang H, Zheng, Ha. Zhang Xh. Engineered Bacterial Bioreactor for Tumor Therapy via Fenton-Like reaction with localized H2O2 generation. Adv Mater. 2019;31(16).
75. Deng X Yang W Shao Z Zhao Y Genetically modified bacteria for targeted phototherapy of tumor Biomaterials 2021 272 120809 10.1016/j.biomaterials.2021.120809 33839624
Deng X, Yang W, Shao Z, Zhao Y. Genetically modified bacteria for targeted phototherapy of tumor. Biomaterials. 2021;272:120809.33839624 10.1016/j.biomaterials.2021.120809
76. Feng X Yang G Liu L A convenient preparation of multi-spectral microparticles by bacteria-mediated assemblies of conjugated polymer nanoparticles for cell imaging and barcoding Adv Mater 2012 24 5 637 41 10.1002/adma.201102026 21932281
Feng X, Yang G, Liu L, et al. A convenient preparation of multi-spectral microparticles by bacteria-mediated assemblies of conjugated polymer nanoparticles for cell imaging and barcoding. Adv Mater. 2012;24(5):637–41.21932281 10.1002/adma.201102026
77. Wu M Wu W Duan Y Li X Liu B Photosensitizer-Bacteria bio-hybrids promote photodynamic Cancer cell ablation and intracellular protein delivery Chem Mater 2019 31 18 7212 20 10.1021/acs.chemmater.9b01518
Wu M, Wu W, Duan Y, Li X, Liu B. Photosensitizer-Bacteria bio-hybrids promote photodynamic Cancer cell ablation and intracellular protein delivery. Chem Mater. 2019;31(18):7212–20.10.1021/acs.chemmater.9b01518
78. Akolpoglu M Alapan Y Dogan N Magnetically steerable bacterial microrobots moving in 3D biological matrices for stimuli-responsive cargo delivery Sci Adv 2022 8 28 eabo6163 10.1126/sciadv.abo6163 35857516
Akolpoglu M, Alapan Y, Dogan N, et al. Magnetically steerable bacterial microrobots moving in 3D biological matrices for stimuli-responsive cargo delivery. Sci Adv. 2022;8(28):eabo6163.35857516 10.1126/sciadv.abo6163
79. Dong H Sarkes D Rice J Hurley M Fu A Stratis-Cullum D Living Bacteria-nanoparticle hybrids mediated through surface-displayed peptides Langmuir 2018 34 20 5837 48 10.1021/acs.langmuir.8b00114 29692178
Dong H, Sarkes D, Rice J, Hurley M, Fu A, Stratis-Cullum D. Living Bacteria-nanoparticle hybrids mediated through surface-displayed peptides. Langmuir. 2018;34(20):5837–48.29692178 10.1021/acs.langmuir.8b00114
80. Hu Q Wu M Fang C Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy Nano Lett 2015 15 4 2732 9 10.1021/acs.nanolett.5b00570 25806599
Hu Q, Wu M, Fang C, et al. Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 2015;15(4):2732–9.25806599 10.1021/acs.nanolett.5b00570
81. Chen W Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy ACS Nano 2018 12 6 5995 6005 10.1021/acsnano.8b02235 29786420
Chen W. Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy. ACS Nano. 2018;12(6):5995–6005.29786420 10.1021/acsnano.8b02235
82. Ektate K Munteanu M Ashar H Malayer J Ranjan A Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots) Sci Rep 2018 8 1 13062 10.1038/s41598-018-30106-4 30166607
Ektate K, Munteanu M, Ashar H, Malayer J, Ranjan A. Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots). Sci Rep. 2018;8(1):13062.30166607 10.1038/s41598-018-30106-4
83. Zheng S Han Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella Typhimurium) Sens Actuat B-Chem 2016 3 217 24
Zheng S, Han, et al. Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella Typhimurium). Sens Actuat B-Chem. 2016;3:217–24.
84. Zoaby N Shainsky-Roitman J Badarneh S Autonomous bacterial nanoswimmers target cancer J Control Release 2017 257 68 75 10.1016/j.jconrel.2016.10.006 27744036
Zoaby N, Shainsky-Roitman J, Badarneh S, et al. Autonomous bacterial nanoswimmers target cancer. J Control Release. 2017;257:68–75.27744036 10.1016/j.jconrel.2016.10.006
85. Wang C, Zhong L, Xu J et al. Oncolytic mineralized bacteria as potent locally administered immunotherapeutics. Nat Biomed Eng. 2024.
86. Guo L Ding J Zhou W Converting bacteria into autologous tumor vaccine via surface biomineralization of calcium carbonate for enhanced immunotherapy Acta Pharm Sin B 2023 13 12 5074 90 10.1016/j.apsb.2023.08.028 38045045
Guo L, Ding J, Zhou W. Converting bacteria into autologous tumor vaccine via surface biomineralization of calcium carbonate for enhanced immunotherapy. Acta Pharm Sin B. 2023;13(12):5074–90.38045045 10.1016/j.apsb.2023.08.028
87. Park W, Cho S, Huang X, Larson A, Kim D. Branched gold nanoparticle coating of Clostridium novyi-NT spores for CT-Guided Intratumoral Injection. Small. 2017;13(5).
88. Luo C Huang C Su C Yeh C Bacteria-mediated hypoxia-specific delivery of nanoparticles for Tumors Imaging and Therapy Nano Lett 2016 16 6 3493 9 10.1021/acs.nanolett.6b00262 27148804
Luo C, Huang C, Su C, Yeh C. Bacteria-mediated hypoxia-specific delivery of nanoparticles for Tumors Imaging and Therapy. Nano Lett. 2016;16(6):3493–9.27148804 10.1021/acs.nanolett.6b00262
89. Felfoul O Mohammadi M Taherkhani S Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions Nat Nanotechnol 2016 11 11 941 7 10.1038/nnano.2016.137 27525475
Felfoul O, Mohammadi M, Taherkhani S, et al. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nat Nanotechnol. 2016;11(11):941–7.27525475 10.1038/nnano.2016.137
90. Samira T Covalent binding of nanoliposomes to the surface of magnetotactic bacteria for the synthesis of self-propelled therapeutic agents ACS Nano 2014 8 5 5049 60 10.1021/nn5011304 24684397
Samira T. Covalent binding of nanoliposomes to the surface of magnetotactic bacteria for the synthesis of self-propelled therapeutic agents. ACS Nano. 2014;8(5):5049–60.24684397 10.1021/nn5011304
91. Ye P Li F Zou J In situ Generation of Gold nanoparticles on Bacteria-derived magnetosomes for imaging-guided Starving/Chemodynamic/Photothermal synergistic therapy against Cancer Adv Funct Mater 2022 32 17 2110063 10.1002/adfm.202110063
Ye P, Li F, Zou J, et al. In situ Generation of Gold nanoparticles on Bacteria-derived magnetosomes for imaging-guided Starving/Chemodynamic/Photothermal synergistic therapy against Cancer. Adv Funct Mater. 2022;32(17):2110063.10.1002/adfm.202110063
92. Xiao S Shi H Zhang Y Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer J Nanobiotechnol 2022 20 1 178 10.1186/s12951-022-01373-1
Xiao S, Shi H, Zhang Y, et al. Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer. J Nanobiotechnol. 2022;20(1):178.10.1186/s12951-022-01373-1
93. Li J Dai J Zhao L Bioactive Bacteria/MOF hybrids can achieve targeted synergistic chemotherapy and chemodynamic therapy against breast tumors Adv Funct Mater 2023 33 42 2303254 10.1002/adfm.202303254
Li J, Dai J, Zhao L, et al. Bioactive Bacteria/MOF hybrids can achieve targeted synergistic chemotherapy and chemodynamic therapy against breast tumors. Adv Funct Mater. 2023;33(42):2303254.10.1002/adfm.202303254
94. Shi H Chen L Liu Y Bacteria-driven Tumor Microenvironment-Sensitive nanoparticles Targeting Hypoxic regions enhances the Chemotherapy Outcome of Lung Cancer Int J Nanomed 2023 18 1299 315 10.2147/IJN.S396863
Shi H, Chen L, Liu Y, et al. Bacteria-driven Tumor Microenvironment-Sensitive nanoparticles Targeting Hypoxic regions enhances the Chemotherapy Outcome of Lung Cancer. Int J Nanomed. 2023;18:1299–315.10.2147/IJN.S396863
95. Li Y Li Y Leng Q Anaerobic bacteria mediated ‘smart missile’ targeting tumor hypoxic area enhances the therapeutic outcome of lung cancer Chem Eng J 2022 438 135566 10.1016/j.cej.2022.135566
Li Y, Li Y, Leng Q, et al. Anaerobic bacteria mediated ‘smart missile’ targeting tumor hypoxic area enhances the therapeutic outcome of lung cancer. Chem Eng J. 2022;438:135566.10.1016/j.cej.2022.135566
96. He T Wang L Gou S Enhanced immunogenic cell death and Antigen Presentation via Engineered Bifidobacterium bifidum to Boost Chemo-Immunotherapy ACS Nano 2023 17 11 9953 71 10.1021/acsnano.2c11474 37212750
He T, Wang L, Gou S, et al. Enhanced immunogenic cell death and Antigen Presentation via Engineered Bifidobacterium bifidum to Boost Chemo-Immunotherapy. ACS Nano. 2023;17(11):9953–71.37212750 10.1021/acsnano.2c11474
97. Luo Y Xu D Gao X Nanoparticles conjugated with bacteria targeting tumors for precision imaging and therapy Biochem Biophys Res Commun 2019 514 4 1147 53 10.1016/j.bbrc.2019.05.074 31103266
Luo Y, Xu D, Gao X, et al. Nanoparticles conjugated with bacteria targeting tumors for precision imaging and therapy. Biochem Biophys Res Commun. 2019;514(4):1147–53.31103266 10.1016/j.bbrc.2019.05.074
98. Wu W Pu Y Yao H Lin H Shi J Microbiotic nanomedicine for tumor-specific chemotherapy-synergized innate/adaptive antitumor immunity Nano Today 2022 42 101377 101377 10.1016/j.nantod.2022.101377
Wu W, Pu Y, Yao H, Lin H, Shi J. Microbiotic nanomedicine for tumor-specific chemotherapy-synergized innate/adaptive antitumor immunity. Nano Today. 2022;42:101377–101377.10.1016/j.nantod.2022.101377
99. Wang W Zhang L Zhang Y A self-adaptive pyroptosis inducer: optimizing the Catalytic Microenvironment of nanozymes by membrane-adhered microbe enables Potent Cancer Immunotherapy Adv Mater 2024 36 14 2310063 10.1002/adma.202310063
Wang W, Zhang L, Zhang Y, et al. A self-adaptive pyroptosis inducer: optimizing the Catalytic Microenvironment of nanozymes by membrane-adhered microbe enables Potent Cancer Immunotherapy. Adv Mater. 2024;36(14):2310063.10.1002/adma.202310063
100. Haosheng S, Changyu Z, Shengjie L et al. Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy. Nat Commun. 2024;15(1).
101. Chen Q-W Liu X-H Fan J-X Self-mineralized photothermal Bacteria hybridizing with Mitochondria-targeted metal–Organic frameworks for Augmenting Photothermal Tumor Therapy Adv Funct Mater 2020 30 14 1909806 10.1002/adfm.201909806
Chen Q-W, Liu X-H, Fan J-X, et al. Self-mineralized photothermal Bacteria hybridizing with Mitochondria-targeted metal–Organic frameworks for Augmenting Photothermal Tumor Therapy. Adv Funct Mater. 2020;30(14):1909806.10.1002/adfm.201909806
102. Xi M, Deng Z, Zhang C et al. FeS-based cascade bioreactors driven by Shewanella oneidensis MR-1 for efficient chemodynamic therapy with augmented antitumor immunity. Nano Today. 2024/04/01/ 2024;55:102165.
103. Akin D Sturgis J Ragheb K Bacteria-mediated delivery of nanoparticles and cargo into cells Nat Nanotechnol 2007 2 7 441 9 10.1038/nnano.2007.149 18654330
Akin D, Sturgis J, Ragheb K, et al. Bacteria-mediated delivery of nanoparticles and cargo into cells. Nat Nanotechnol. 2007;2(7):441–9.18654330 10.1038/nnano.2007.149
104. Dróżdż M Makuch S Cieniuch G Woźniak M Ziółkowski P Obligate and facultative anaerobic bacteria in targeted cancer therapy: current strategies and clinical applications Life Sci 2020 261 118296 10.1016/j.lfs.2020.118296 32822716
Dróżdż M, Makuch S, Cieniuch G, Woźniak M, Ziółkowski P. Obligate and facultative anaerobic bacteria in targeted cancer therapy: current strategies and clinical applications. Life Sci. 2020;261:118296.32822716 10.1016/j.lfs.2020.118296
105. Li Q Chen H Feng X Nanoparticle-regulated semiartificial magnetotactic Bacteria with tunable magnetic moment and magnetic sensitivity Small 2019 15 15 e1900427 10.1002/smll.201900427 30844151
Li Q, Chen H, Feng X, et al. Nanoparticle-regulated semiartificial magnetotactic Bacteria with tunable magnetic moment and magnetic sensitivity. Small. 2019;15(15):e1900427.30844151 10.1002/smll.201900427
106. Chen W Zhu Y Chen J Potentiating the systemic immunity by Bacteria-delivered Sting activation in a Tumor Microenvironment Adv Funct Mater 2023 33 2307001 10.1002/adfm.202307001
Chen W, Zhu Y, Chen J, et al. Potentiating the systemic immunity by Bacteria-delivered Sting activation in a Tumor Microenvironment. Adv Funct Mater. 2023;33:2307001.10.1002/adfm.202307001
107. Park S Park S Cho S New paradigm for tumor theranostic methodology using bacteria-based microrobot Sci Rep 2013 3 3394 10.1038/srep03394 24292152
Park S, Park S, Cho S, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013;3:3394.24292152 10.1038/srep03394
108. Wang X Niu M Fan J Chen Q Zhang X In situ photoelectric Bacteria enhance the production of tetrodotoxin for Antitumor Therapy Nano Lett 2021 21 10 4270 9 10.1021/acs.nanolett.1c00408 33955768
Wang X, Niu M, Fan J, Chen Q, Zhang X. In situ photoelectric Bacteria enhance the production of tetrodotoxin for Antitumor Therapy. Nano Lett. 2021;21(10):4270–9.33955768 10.1021/acs.nanolett.1c00408
109. Beveridge TJ Graham LL Surface layers of bacteria Microbiol Rev 1992 55 4 684 705 10.1128/mr.55.4.684-705.1991
Beveridge TJ, Graham LL. Surface layers of bacteria. Microbiol Rev. 1992;55(4):684–705.10.1128/mr.55.4.684-705.1991
110. Liu L, He H, Luo Z, Zhou H, Cai L. In situ photocatalyzed oxygen generation with photosynthetic Bacteria to Enable Robust Immunogenic Photodynamic Therapy in Triple-negative breast Cancer. Adv Funct Mater. 2020;30(10).
111. Bi X Yin J Guanbang AC Liu CF Chemical and enzymatic strategies for bacterial and mammalian cell Surface Engineering Chemistry 2018 24 32 8042 50 10.1002/chem.201705049 29341307
Bi X, Yin J, Guanbang AC, Liu CF. Chemical and enzymatic strategies for bacterial and mammalian cell Surface Engineering. Chemistry. 2018;24(32):8042–50.29341307 10.1002/chem.201705049
112. Theile CS Witte MD Blom AEM Kundrat L Ploegh HL Guimaraes CP Site-specific N-terminal labeling of proteins using sortase-mediated reactions Nat Protoc 2013 8 9 1800 7 10.1038/nprot.2013.102 23989674
Theile CS, Witte MD, Blom AEM, Kundrat L, Ploegh HL, Guimaraes CP. Site-specific N-terminal labeling of proteins using sortase-mediated reactions. Nat Protoc. 2013;8(9):1800–7.23989674 10.1038/nprot.2013.102
113. Han L, Terasaki O, Che S. Carboxylic group functionalized ordered mesoporous silicas. J Mater Chem. 2011;(30).
114. Xie S Zhao L Song X Tang M Mo C Li X Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release J Control Release 2017 268 390 9 10.1016/j.jconrel.2017.10.041 29101053
Xie S, Zhao L, Song X, Tang M, Mo C, Li X. Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. J Control Release. 2017;268:390–9.29101053 10.1016/j.jconrel.2017.10.041
115. Stephan MT Moon JJ Um SH Bershteyn A Irvine DJ Therapeutic cell engineering with surface-conjugated synthetic nanoparticles Nat Med 2010 16 9 1035 41 10.1038/nm.2198 20711198
Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010;16(9):1035–41.20711198 10.1038/nm.2198
116. Luo H Chen Y Kuang X Chemical reaction-mediated covalent localization of bacteria Nat Commun 2022 13 1 7808 10.1038/s41467-022-35579-6 36528693
Luo H, Chen Y, Kuang X, et al. Chemical reaction-mediated covalent localization of bacteria. Nat Commun. 2022;13(1):7808.36528693 10.1038/s41467-022-35579-6
117. Wei X Du M Chen Z Yuan Z Recent advances in Bacteria-based Cancer Treatment Cancers 2022 14 19 4945 10.3390/cancers14194945 36230868
Wei X, Du M, Chen Z, Yuan Z. Recent advances in Bacteria-based Cancer Treatment. Cancers. 2022;14(19):4945.36230868 10.3390/cancers14194945
118. Wu W Pu Y Gao S Bacterial metabolism-initiated nanocatalytic Tumor Immunotherapy Nanomicro Lett 2022 14 1 220 36367591
Wu W, Pu Y, Gao S, et al. Bacterial metabolism-initiated nanocatalytic Tumor Immunotherapy. Nanomicro Lett. 2022;14(1):220.36367591
119. HARDEN V HARRIS J The isoelectric point of bacterial cells J Bacteriol 1953 65 2 198 202 10.1128/jb.65.2.198-202.1953 13034716
HARDEN V, HARRIS J. The isoelectric point of bacterial cells. J Bacteriol. 1953;65(2):198–202.13034716 10.1128/jb.65.2.198-202.1953
120. Lin S Wu F Zhang Y Surface-modified bacteria: synthesis, functionalization and biomedical applications Chem Soc Rev 2023 52 19 6617 43 10.1039/D3CS00369H 37724854
Lin S, Wu F, Zhang Y, et al. Surface-modified bacteria: synthesis, functionalization and biomedical applications. Chem Soc Rev. 2023;52(19):6617–43.37724854 10.1039/D3CS00369H
121. Akolpoglu M Dogan N Bozuyuk U Ceylan H Kizilel S Sitti M High-yield production of Biohybrid Microalgae for On-Demand Cargo Delivery Adv Sci 2020 7 16 2001256 10.1002/advs.202001256
Akolpoglu M, Dogan N, Bozuyuk U, Ceylan H, Kizilel S, Sitti M. High-yield production of Biohybrid Microalgae for On-Demand Cargo Delivery. Adv Sci. 2020;7(16):2001256.10.1002/advs.202001256
122. Park J Yang S Lee J Ko E Hong D Choi I Nanocoating of single cells: from maintenance of cell viability to manipulation of cellular activities Adv Mater 2014 26 13 2001 10 10.1002/adma.201304568 24452932
Park J, Yang S, Lee J, Ko E, Hong D, Choi I. Nanocoating of single cells: from maintenance of cell viability to manipulation of cellular activities. Adv Mater. 2014;26(13):2001–10.24452932 10.1002/adma.201304568
123. Das S Liang J Schmidt M Laffir F Marsili E Biomineralization mechanism of gold by zygomycete fungi Rhizopus oryzae ACS Nano 2012 6 7 6165 73 10.1021/nn301502s 22708541
Das S, Liang J, Schmidt M, Laffir F, Marsili E. Biomineralization mechanism of gold by zygomycete fungi Rhizopus oryzae. ACS Nano. 2012;6(7):6165–73.22708541 10.1021/nn301502s
124. Yuan H Liu Z Liu L Lv F Wang Y Wang S Cationic conjugated polymers for discrimination of microbial pathogens Adv Mater 2014 26 25 4333 8 10.1002/adma.201400636 24737340
Yuan H, Liu Z, Liu L, Lv F, Wang Y, Wang S. Cationic conjugated polymers for discrimination of microbial pathogens. Adv Mater. 2014;26(25):4333–8.24737340 10.1002/adma.201400636
125. Li L, Liu L, Li L et al. Chitosan coated bacteria responsive metal-polyphenol coating as efficient platform for wound healing. Compos Part B-Eng. 2022:234.
126. YufeiTang ZL KangZhao SF Positively charged and flexible SiO2@ZrO2 nanofibrous membranes and their application in adsorption and separation RSC Adv 2018 8 23 13018 25 10.1039/C8RA01899E 35541269
YufeiTang ZL, KangZhao SF. Positively charged and flexible SiO2@ZrO2 nanofibrous membranes and their application in adsorption and separation. RSC Adv. 2018;8(23):13018–25.35541269 10.1039/C8RA01899E
127. Li Z Ma J Ruan J Zhuang X Using positively charged magnetic nanoparticles to capture Bacteria at Ultralow Concentration Nanoscale Res Lett 2019 14 1 195 10.1186/s11671-019-3005-z 31165285
Li Z, Ma J, Ruan J, Zhuang X. Using positively charged magnetic nanoparticles to capture Bacteria at Ultralow Concentration. Nanoscale Res Lett. 2019;14(1):195.31165285 10.1186/s11671-019-3005-z
128. Cao Z Wang X Pang Y Cheng S Liu J Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment Nat Commun 2019 10 1 5783 10.1038/s41467-019-13727-9 31857577
Cao Z, Wang X, Pang Y, Cheng S, Liu J. Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment. Nat Commun. 2019;10(1):5783.31857577 10.1038/s41467-019-13727-9
129. Li J Sun W Yang Z Rational design of self-assembled Cationic Porphyrin-based nanoparticles for efficient photodynamic inactivation of Bacteria ACS Appl Mater Interfaces 2020 12 49 54378 86 10.1021/acsami.0c15244 33226224
Li J, Sun W, Yang Z, et al. Rational design of self-assembled Cationic Porphyrin-based nanoparticles for efficient photodynamic inactivation of Bacteria. ACS Appl Mater Interfaces. 2020;12(49):54378–86.33226224 10.1021/acsami.0c15244
130. Feng P Cao Z Wang X Li J Liu J On-Demand bacterial reactivation by restraining within a Triggerable Nanocoating Adv Mater 2020 32 34 e2002406 10.1002/adma.202002406 32686247
Feng P, Cao Z, Wang X, Li J, Liu J. On-Demand bacterial reactivation by restraining within a Triggerable Nanocoating. Adv Mater. 2020;32(34):e2002406.32686247 10.1002/adma.202002406
131. Hou W Li J Cao Z Decorating Bacteria with a therapeutic nanocoating for synergistically enhanced Biotherapy Small 2021 17 37 e2101810 10.1002/smll.202101810 34365713
Hou W, Li J, Cao Z, et al. Decorating Bacteria with a therapeutic nanocoating for synergistically enhanced Biotherapy. Small. 2021;17(37):e2101810.34365713 10.1002/smll.202101810
132. Wang J Chen Q Luo G A self-driven Bioreactor based on Bacterium-Metal-Organic Framework Biohybrids for Boosting Chemotherapy Cyclic Lactate Catabolism ACS Nano 2021 15 11 17870 84 10.1021/acsnano.1c06123 34747172
Wang J, Chen Q, Luo G, et al. A self-driven Bioreactor based on Bacterium-Metal-Organic Framework Biohybrids for Boosting Chemotherapy Cyclic Lactate Catabolism. ACS Nano. 2021;15(11):17870–84.34747172 10.1021/acsnano.1c06123
133. Ding S Liu Z Huang C Zeng N Li Q Novel Engineered Bacterium/Black Phosphorus Quantum Dot Hybrid System for Hypoxic Tumor Targeting and efficient photodynamic therapy ACS Appl Mater Interfaces 2021 13 8 10564 73 10.1021/acsami.0c20254 33605723
Ding S, Liu Z, Huang C, Zeng N, Li Q. Novel Engineered Bacterium/Black Phosphorus Quantum Dot Hybrid System for Hypoxic Tumor Targeting and efficient photodynamic therapy. ACS Appl Mater Interfaces. 2021;13(8):10564–73.33605723 10.1021/acsami.0c20254
134. Cheng W, Zeng X, Chen H, Li Z, Zhao Y. Versatile polydopamine platforms: synthesis and promising applications for Surface Modification and Advanced Nanomedicine. ACS Nano. 2019;13(8).
135. Pan C Li J Hou W Polymerization-mediated multifunctionalization of living cells for enhanced cell-based therapy Adv Mater 2021 33 13 e2007379 10.1002/adma.202007379 33629757
Pan C, Li J, Hou W, et al. Polymerization-mediated multifunctionalization of living cells for enhanced cell-based therapy. Adv Mater. 2021;33(13):e2007379.33629757 10.1002/adma.202007379
136. Hyre DE Le TI Merritt EA Cooperative hydrogen bond interactions in the streptavidin-biotin system Protein Sci 2006 15 3 459 67 10.1110/ps.051970306 16452627
Hyre DE, Le TI, Merritt EA, et al. Cooperative hydrogen bond interactions in the streptavidin-biotin system. Protein Sci. 2006;15(3):459–67.16452627 10.1110/ps.051970306
137. Park SJ Park SH Cho S New paradigm for tumor theranostic methodology using bacteria-based microrobot Sci Rep 2013 3 3394 10.1038/srep03394 24292152
Park SJ, Park SH, Cho S, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013;3:3394.24292152 10.1038/srep03394
138. Dundas CM Demonte D Park S Streptavidin–biotin technology: improvements and innovations in chemical and biological applications Appl Microbiol Biotechnol 2013 97 21 9343 53 10.1007/s00253-013-5232-z 24057405
Dundas CM, Demonte D, Park S. Streptavidin–biotin technology: improvements and innovations in chemical and biological applications. Appl Microbiol Biotechnol. 2013;97(21):9343–53.24057405 10.1007/s00253-013-5232-z
139. Chivers CE Koner AL Lowe ED Howarth M How the biotin–streptavidin interaction was made even stronger: investigation via crystallography and a chimaeric tetramer Biochem J 2011 435 1 55 63 10.1042/BJ20101593 21241253
Chivers CE, Koner AL, Lowe ED, Howarth M. How the biotin–streptavidin interaction was made even stronger: investigation via crystallography and a chimaeric tetramer. Biochem J. 2011;435(1):55–63.21241253 10.1042/BJ20101593
140. Akolpoglu MB Alapan Y Dogan NO Magnetically steerable bacterial microrobots moving in 3D biological matrices for stimuli-responsive cargo delivery Sci Adv 2022 8 28 eabo6163 10.1126/sciadv.abo6163 35857516
Akolpoglu MB, Alapan Y, Dogan NO, et al. Magnetically steerable bacterial microrobots moving in 3D biological matrices for stimuli-responsive cargo delivery. Sci Adv. 2022;8(28):eabo6163.35857516 10.1126/sciadv.abo6163
141. Luo CH Huang CT Su CH Yeh CS Bacteria-mediated hypoxia-specific delivery of nanoparticles for Tumors Imaging and Therapy Nano Lett 2016 16 6 3493 9 10.1021/acs.nanolett.6b00262 27148804
Luo CH, Huang CT, Su CH, Yeh CS. Bacteria-mediated hypoxia-specific delivery of nanoparticles for Tumors Imaging and Therapy. Nano Lett. 2016;16(6):3493–9.27148804 10.1021/acs.nanolett.6b00262
142. Nour Z Autonomous bacterial nanoswimmers target cancer J Control Release 2017 257 68 75 10.1016/j.jconrel.2016.10.006 27744036
Nour Z. Autonomous bacterial nanoswimmers target cancer. J Control Release. 2017;257:68–75.27744036 10.1016/j.jconrel.2016.10.006
143. Tsong TY Electroporation of cell membranes Adv Anat Embryol Cell Biol 1991 60 2 297 306
Tsong TY. Electroporation of cell membranes. Adv Anat Embryol Cell Biol. 1991;60(2):297–306.
144. Liu Y Zhou M Luo D Bacteria-mediated in vivo delivery of quantum dots into solid tumor Biochem Biophys Res Commun 2012 425 4 769 74 10.1016/j.bbrc.2012.07.150 22885241
Liu Y, Zhou M, Luo D, et al. Bacteria-mediated in vivo delivery of quantum dots into solid tumor. Biochem Biophys Res Commun. 2012;425(4):769–74.22885241 10.1016/j.bbrc.2012.07.150
145. Kumar M Tegge W Wangoo N Jain R Sharma R Insights into cell penetrating peptide conjugated gold nanoparticles for internalization into bacterial cells Biophys Chem 2018 237 38 46 10.1016/j.bpc.2018.03.005 29656216
Kumar M, Tegge W, Wangoo N, Jain R, Sharma R. Insights into cell penetrating peptide conjugated gold nanoparticles for internalization into bacterial cells. Biophys Chem. 2018;237:38–46.29656216 10.1016/j.bpc.2018.03.005
146. Beveridge T Murray R Sites of metal deposition in the cell wall of Bacillus subtilis J Bacteriol 1980 141 2 876 87 10.1128/jb.141.2.876-887.1980 6767692
Beveridge T, Murray R. Sites of metal deposition in the cell wall of Bacillus subtilis. J Bacteriol. 1980;141(2):876–87.6767692 10.1128/jb.141.2.876-887.1980
147. Yin T Diao Z Blum N Qiu L Ma A Huang P Engineering Bacteria and bionic bacterial derivatives with nanoparticles for Cancer Therapy Small 2022 18 12 e2104643 10.1002/smll.202104643 34908239
Yin T, Diao Z, Blum N, Qiu L, Ma A, Huang P. Engineering Bacteria and bionic bacterial derivatives with nanoparticles for Cancer Therapy. Small. 2022;18(12):e2104643.34908239 10.1002/smll.202104643
148. Park T Lee S Heo N Seo T In vivo synthesis of diverse metal nanoparticles by recombinant Escherichia coli Angew Chem Int Ed Engl 2010 49 39 7019 24 10.1002/anie.201001524 20842627
Park T, Lee S, Heo N, Seo T. In vivo synthesis of diverse metal nanoparticles by recombinant Escherichia coli. Angew Chem Int Ed Engl. 2010;49(39):7019–24.20842627 10.1002/anie.201001524
149. Lina G, Jinsong D, Wenhu Z. Converting bacteria into autologous tumor vaccine via surface biomineralization of calcium carbonate for enhanced immunotherapy. Acta Pharm Sin B. 2023;13(12).
150. Pan P Dong X Chen Y Zeng X Zhang X Engineered Bacteria for enhanced radiotherapy against breast carcinoma ACS Nano 2022 16 1 801 12 10.1021/acsnano.1c08350 35029367
Pan P, Dong X, Chen Y, Zeng X, Zhang X. Engineered Bacteria for enhanced radiotherapy against breast carcinoma. ACS Nano. 2022;16(1):801–12.35029367 10.1021/acsnano.1c08350
151. Xiande L Shengnan Radiotherapy combined with an engineered Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer Exp Anim 2016 65 4 413 8 10.1538/expanim.16-0033 27301721
Xiande L, Shengnan, et al. Radiotherapy combined with an engineered Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer. Exp Anim. 2016;65(4):413–8.27301721 10.1538/expanim.16-0033
152. Dinesh C 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect Oncotarget 2017 8 13 20729 40 10.18632/oncotarget.15117 28186976
Dinesh C. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Oncotarget. 2017;8(13):20729–40.28186976 10.18632/oncotarget.15117
153. Jin-Xuan F Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration Nano Lett 2018 18 4 2373 80 10.1021/acs.nanolett.7b05323 29558152
Jin-Xuan F. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration. Nano Lett. 2018;18(4):2373–80.29558152 10.1021/acs.nanolett.7b05323
154. Wang L Qin W Xu W Bacteria-mediated tumor therapy via Photothermally-programmed Cytolysin A expression Small 2021 17 40 e2102932 10.1002/smll.202102932 34472212
Wang L, Qin W, Xu W, et al. Bacteria-mediated tumor therapy via Photothermally-programmed Cytolysin A expression. Small. 2021;17(40):e2102932.34472212 10.1002/smll.202102932
155. Chu B Yang Y Tang J Song B He Y Wang H Trojan Nanobacteria System for Photothermal Programmable Destruction of Deep Tumor Tissues Angew Chem Int Ed Engl 2022 61 36 e202208422 10.1002/anie.202208422 35736400
Chu B, Yang Y, Tang J, Song B, He Y, Wang H. Trojan Nanobacteria System for Photothermal Programmable Destruction of Deep Tumor Tissues. Angew Chem Int Ed Engl. 2022;61(36):e202208422.35736400 10.1002/anie.202208422
156. Ding S Liu Z Huang C Zeng N Jiang W Li Q Novel Engineered Bacterium/Black Phosphorus Quantum Dot Hybrid System for Hypoxic Tumor Targeting and efficient photodynamic therapy ACS Appl Mater Interfaces 2021 13 8 10564 73 10.1021/acsami.0c20254 33605723
Ding S, Liu Z, Huang C, Zeng N, Jiang W, Li Q. Novel Engineered Bacterium/Black Phosphorus Quantum Dot Hybrid System for Hypoxic Tumor Targeting and efficient photodynamic therapy. ACS Appl Mater Interfaces. 2021;13(8):10564–73.33605723 10.1021/acsami.0c20254
157. Ma X Liang X Li Y Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field Nat Commun 2023 14 1 1606 10.1038/s41467-023-37225-1 36959204
Ma X, Liang X, Li Y, et al. Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field. Nat Commun. 2023;14(1):1606.36959204 10.1038/s41467-023-37225-1
158. Guo L Chen H Ding J Rong P Sun M Zhou W SalmonellaSurface engineering with pH-responsive polyserotonin and self-activated DNAzyme for better microbial therapy of tumor Exploration 2023 3 6 20230017 10.1002/EXP.20230017 38264692
Guo L, Chen H, Ding J, Rong P, Sun M, Zhou W. SalmonellaSurface engineering with pH-responsive polyserotonin and self-activated DNAzyme for better microbial therapy of tumor. Exploration. 2023;3(6):20230017.38264692 10.1002/EXP.20230017
159. Fan J Peng M Wang H Engineered Bacterial Bioreactor for Tumor Therapy via Fenton-Like reaction with localized H O generation Adv Mater 2019 31 16 e1808278 10.1002/adma.201808278 30803049
Fan J, Peng M, Wang H, et al. Engineered Bacterial Bioreactor for Tumor Therapy via Fenton-Like reaction with localized H O generation. Adv Mater. 2019;31(16):e1808278.30803049 10.1002/adma.201808278
160. Zhang W Liu J Li X Precise chemodynamic therapy of Cancer by Trifunctional Bacterium-Based Nanozymes ACS Nano 2021 15 12 19321 33 10.1021/acsnano.1c05605 34851608
Zhang W, Liu J, Li X, et al. Precise chemodynamic therapy of Cancer by Trifunctional Bacterium-Based Nanozymes. ACS Nano. 2021;15(12):19321–33.34851608 10.1021/acsnano.1c05605
161. Hou X Jiang J Tian Z Wei L Autophagy and Tumour Chemotherapy Adv Exp Med Biol 2020 1207 351 74 10.1007/978-981-15-4272-5_24 32671759
Hou X, Jiang J, Tian Z, Wei L. Autophagy and Tumour Chemotherapy. Adv Exp Med Biol. 2020;1207:351–74.32671759 10.1007/978-981-15-4272-5_24
162. Pérez-Herrero E Fernández-Medarde A Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy Eur J Pharm Biopharm 2015 93 52 79 10.1016/j.ejpb.2015.03.018 25813885
Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.25813885 10.1016/j.ejpb.2015.03.018
163. Song S Vuai M Zhong M The role of bacteria in cancer therapy - enemies in the past, but allies at present IInfect Agent Cancer 2018 13 9 10.1186/s13027-018-0180-y
Song S, Vuai M, Zhong M. The role of bacteria in cancer therapy - enemies in the past, but allies at present. IInfect Agent Cancer. 2018;13:9.10.1186/s13027-018-0180-y
164. Horsman M Mortensen L Petersen J Busk M Overgaard J Imaging hypoxia to improve radiotherapy outcome Nat Rev Clin Oncol 2012 9 12 674 87 10.1038/nrclinonc.2012.171 23149893
Horsman M, Mortensen L, Petersen J, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):674–87.23149893 10.1038/nrclinonc.2012.171
165. Pan R Ryan J Pan D Wucherpfennig K Letai A Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis Cell 2022 185 9 1521 38 10.1016/j.cell.2022.03.030 35447071
Pan R, Ryan J, Pan D, Wucherpfennig K, Letai A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022;185(9):1521–38.35447071 10.1016/j.cell.2022.03.030
166. Van Leent MMT, Priem B, Schrijver DP et al. Regulating trained immunity with nanomedicine. Nat Rev Mater. 2022;(6):7.
167. Garland K Sheehy T Wilson J Chemical and Biomolecular strategies for STING pathway activation in Cancer Immunotherapy Chem Rev 2022 122 6 5977 6039 10.1021/acs.chemrev.1c00750 35107989
Garland K, Sheehy T, Wilson J. Chemical and Biomolecular strategies for STING pathway activation in Cancer Immunotherapy. Chem Rev. 2022;122(6):5977–6039.35107989 10.1021/acs.chemrev.1c00750
168. Xingshu L Jonathan F Clinical development and potential of photothermal and photodynamic therapies for cancer Nat Rev Clin Oncol 2020 17 11 657 74 10.1038/s41571-020-0410-2 32699309
Xingshu L, Jonathan F, et al. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17(11):657–74.32699309 10.1038/s41571-020-0410-2
169. Lv S Miao Y Liu D Song F Recent development of Photothermal agents (PTAs) based on small Organic Molecular dyes ChemBioChem 2020 21 15 2098 110 10.1002/cbic.202000089 32202062
Lv S, Miao Y, Liu D, Song F. Recent development of Photothermal agents (PTAs) based on small Organic Molecular dyes. ChemBioChem. 2020;21(15):2098–110.32202062 10.1002/cbic.202000089
170. Li C Cheng Y Li D Antitumor Applications of Photothermal agents and Photothermal Synergistic therapies Int J Mol Sci 2022 23 14 7909 10.3390/ijms23147909 35887255
Li C, Cheng Y, Li D, et al. Antitumor Applications of Photothermal agents and Photothermal Synergistic therapies. Int J Mol Sci. 2022;23(14):7909.35887255 10.3390/ijms23147909
171. Nam J Son S Ochyl L Kuai R Schwendeman A Moon J Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer Nat Commun 2018 9 1 1074 10.1038/s41467-018-03473-9 29540781
Nam J, Son S, Ochyl L, Kuai R, Schwendeman A, Moon J. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018;9(1):1074.29540781 10.1038/s41467-018-03473-9
172. Lou X Chen Z He Z Sun M Sun J Bacteria-mediated synergistic Cancer therapy: small Microbiome has a big Hope Nanomicro Lett 2021 13 1 37 34138211
Lou X, Chen Z, He Z, Sun M, Sun J. Bacteria-mediated synergistic Cancer therapy: small Microbiome has a big Hope. Nanomicro Lett. 2021;13(1):37.34138211
173. Fuming C Zhongsheng Z Ze C Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy Biomaterials 2019 214 119226 10.1016/j.biomaterials.2019.119226 31174068
Fuming C, Zhongsheng Z, Ze C, et al. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy. Biomaterials. 2019;214:119226.31174068 10.1016/j.biomaterials.2019.119226
174. Celli J Spring B Rizvi I Imaging and photodynamic therapy: mechanisms, monitoring, and optimization Chem Rev 2010 110 5 2795 838 10.1021/cr900300p 20353192
Celli J, Spring B, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010;110(5):2795–838.20353192 10.1021/cr900300p
175. Dougherty TJ Kaufman JE Goldfarb A Weishaupt KR Boyle D Mittleman A Photoradiation therapy for the treatment of malignant tumors Cancer Res 1978 38 8 2628 35 667856
Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978;38(8):2628–35.667856
176. Chen J Zhu Y Wu C Shi J Nanoplatform-based cascade engineering for cancer therapy Chem Soc Rev 2020 49 24 9057 94 10.1039/D0CS00607F 33112326
Chen J, Zhu Y, Wu C, Shi J. Nanoplatform-based cascade engineering for cancer therapy. Chem Soc Rev. 2020;49(24):9057–94.33112326 10.1039/D0CS00607F
177. Lu H Niu L Yu L Cancer phototherapy with nano-bacteria biohybrids J Control Release 2023 360 133 48 10.1016/j.jconrel.2023.06.009 37315693
Lu H, Niu L, Yu L, et al. Cancer phototherapy with nano-bacteria biohybrids. J Control Release. 2023;360:133–48.37315693 10.1016/j.jconrel.2023.06.009
178. Yunlu D, Zhen Y, Siyuan C et al. Toxic reactive oxygen species enhanced synergistic combination therapy by self-assembled metal-phenolic network nanoparticles. Adv Mater. 2018;30(8).
179. Xiao Y Deng Y Huan W Li J Zhang J Xing M Hollow-structured Fe2O3/Au/SiO2 nanorods with enhanced and recyclable photo-Fenton oxidation for the remediation of organic pollutants Mater Today Chem Mar 2019 11 86 93
Xiao Y, Deng Y, Huan W, Li J, Zhang J, Xing M. Hollow-structured Fe2O3/Au/SiO2 nanorods with enhanced and recyclable photo-Fenton oxidation for the remediation of organic pollutants. Mater Today Chem Mar. 2019;11:86–93.
180. Gu Z Zhu S Yan L Zhao F Zhao Y Graphene-based Smart platforms for Combined Cancer Therapy Adv Mater 2019 31 9 e1800662 10.1002/adma.201800662 30039878
Gu Z, Zhu S, Yan L, Zhao F, Zhao Y. Graphene-based Smart platforms for Combined Cancer Therapy. Adv Mater. 2019;31(9):e1800662.30039878 10.1002/adma.201800662
181. Qinglian H, Min W, Chun F et al. Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 2015;15(4).
182. Dezhi N, Shuang Q, Hui D et al. Biomimetically Engineered demi-Bacteria potentiate vaccination against Cancer. Adv Sci 2017;4(10).
183. Hong D Deborah AS Jeffrey JR Margaret MH Adele JF Dimitra N S-C. Living Bacteria-Nanoparticle Hybrids Mediated through surface-displayed peptides Langmuir 2018 34 20 5837 48 10.1021/acs.langmuir.8b00114 29692178
Hong D, Deborah AS, Jeffrey JR, Margaret MH, Adele JF. Dimitra N S-C. Living Bacteria-Nanoparticle Hybrids Mediated through surface-displayed peptides. Langmuir. 2018;34(20):5837–48.29692178 10.1021/acs.langmuir.8b00114
184. Jin-Xuan F Meng-Yun P He W Engineered Bacterial Bioreactor for Tumor Therapy via Fenton-Like reaction with localized H(2) O(2) generation Adv Mater 2019 31 16 e1808278 10.1002/adma.201808278 30803049
Jin-Xuan F, Meng-Yun P, He W, et al. Engineered Bacterial Bioreactor for Tumor Therapy via Fenton-Like reaction with localized H(2) O(2) generation. Adv Mater. 2019;31(16):e1808278.30803049 10.1002/adma.201808278
185. Jin-Xuan F Zi-Hao L Xin-Hua L Di-Wei Z Ying C Xian-Zheng Z Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration Nano Lett 2018 18 4 2373 80 10.1021/acs.nanolett.7b05323 29558152
Jin-Xuan F, Zi-Hao L, Xin-Hua L, Di-Wei Z, Ying C, Xian-Zheng Z. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration. Nano Lett. 2018;18(4):2373–80.29558152 10.1021/acs.nanolett.7b05323
186. Di-Wei Z Ying C Zi-Hao L Optically-controlled bacterial metabolite for cancer therapy Nat Commun 2018 9 1 1680 10.1038/s41467-018-03233-9 29700283
Di-Wei Z, Ying C, Zi-Hao L, et al. Optically-controlled bacterial metabolite for cancer therapy. Nat Commun. 2018;9(1):1680.29700283 10.1038/s41467-018-03233-9
187. Sun M Ye H Shi Q Both-In-One hybrid Bacteria suppress the Tumor Metastasis and Relapse via Tandem-Amplifying reactive oxygen species-immunity responses Adv Healthc Mater 2021 10 21 e2100950 10.1002/adhm.202100950 34541825
Sun M, Ye H, Shi Q, et al. Both-In-One hybrid Bacteria suppress the Tumor Metastasis and Relapse via Tandem-Amplifying reactive oxygen species-immunity responses. Adv Healthc Mater. 2021;10(21):e2100950.34541825 10.1002/adhm.202100950
188. Kalyani E Cristina MM Harshini A Jerry M Ashish R Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots) Sci Rep 2018 8 1 13062 10.1038/s41598-018-30106-4 30166607
Kalyani E, Cristina MM, Harshini A, Jerry M, Ashish R. Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots). Sci Rep. 2018;8(1):13062.30166607 10.1038/s41598-018-30106-4
189. Zhang H Wang Y Zhu L A bulldozer driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy J Control Release Aug 2023 360 660 71 10.1016/j.jconrel.2023.07.014
Zhang H, Wang Y, Zhu L, et al. A bulldozer driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy. J Control Release Aug. 2023;360:660–71.10.1016/j.jconrel.2023.07.014
190. Yin C Wang Z Dai C Light-triggered photosynthetic engineered bacteria for enhanced-photodynamic therapy by relieving tumor hypoxic microenvironment Theranostics 2023 13 5 1632 48 10.7150/thno.81718 37056566
Yin C, Wang Z, Dai C, et al. Light-triggered photosynthetic engineered bacteria for enhanced-photodynamic therapy by relieving tumor hypoxic microenvironment. Theranostics. 2023;13(5):1632–48.37056566 10.7150/thno.81718
191. B XDA, A WY AZS Genetically modified Bacteria for targeted phototherapy of Tumor Biomaterials 2021 272 120809 10.1016/j.biomaterials.2021.120809 33839624
B XDA, A WY AZS. Genetically modified Bacteria for targeted phototherapy of Tumor. Biomaterials. 2021;272:120809.33839624 10.1016/j.biomaterials.2021.120809
192. Self-Mineralized Photothermal Bacteria. Hybridizing with Mitochondria‐targeted metal–Organic frameworks for Augmenting Photothermal Tumor Therapy. Adv Funct Mater. 2020;30(14).
193. Reghu S Miyako E Bifidobacterium bifidumNanoengineered with optical activity for Photothermal Cancer Immunotheranostics Nano Lett 2022 22 5 1880 8 10.1021/acs.nanolett.1c04037 35179380
Reghu S, Miyako E. Bifidobacterium bifidumNanoengineered with optical activity for Photothermal Cancer Immunotheranostics. Nano Lett. 2022;22(5):1880–8.35179380 10.1021/acs.nanolett.1c04037
194. Chen W He C Qiao N Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses Biomaterials 2022 286 121582 10.1016/j.biomaterials.2022.121582 35609407
Chen W, He C, Qiao N, et al. Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses. Biomaterials. 2022;286:121582.35609407 10.1016/j.biomaterials.2022.121582
195. Reghu S, Iwata S, Komatsu S, Nakajo T, Miyako E. Cancer immunotheranostics using bioactive nanocoated photosynthetic bacterial complexes. Nano Today. 2023/10/01/ 2023;52:101966.
196. Luo W Zhang Z Zhou D Deep tumor penetration of CRISPR-Cas System for Photothermal-Sensitized Immunotherapy via Probiotics Nano Lett 2023 23 17 8081 90 10.1021/acs.nanolett.3c02061 37615340
Luo W, Zhang Z, Zhou D, et al. Deep tumor penetration of CRISPR-Cas System for Photothermal-Sensitized Immunotherapy via Probiotics. Nano Lett. 2023;23(17):8081–90.37615340 10.1021/acs.nanolett.3c02061
197. Wu D Zhao Z Liu H Escherichia coli Nissle 1917-driven microrobots for effective tumor targeted drug delivery and tumor regression Acta Biomater 2023 169 477 88 10.1016/j.actbio.2023.07.051 37532134
Wu D, Zhao Z, Liu H, et al. Escherichia coli Nissle 1917-driven microrobots for effective tumor targeted drug delivery and tumor regression. Acta Biomater. 2023;169:477–88.37532134 10.1016/j.actbio.2023.07.051
198. Zang M, Ji Y, Ding X et al. Trojan nanobacteria hybridized with prodrug nanocapsules for efficient combined tumor therapy. Nano Res. 2023/07/01 2023;16(7):9651–9662.
199. Ji P Chen J Wang H Shi L Tang X Duo Y Bacteria-targeted delivery of black phosphorus quantum dots facilitates photothermal therapy against hypoxic tumors and complementary low-dose radiotherapy Biomater Sci 2023 11 13 4727 40 10.1039/D3BM00206C 37249003
Ji P, Chen J, Wang H, Shi L, Tang X, Duo Y. Bacteria-targeted delivery of black phosphorus quantum dots facilitates photothermal therapy against hypoxic tumors and complementary low-dose radiotherapy. Biomater Sci. 2023;11(13):4727–40.37249003 10.1039/D3BM00206C
200. Lin W Liu Y Wang J Engineered Bacteria labeled with Iridium(III) Photosensitizers for enhanced photodynamic immunotherapy of solid tumors Angew Chem Int Ed Engl 2023 62 43 e202310158 10.1002/anie.202310158 37668526
Lin W, Liu Y, Wang J, et al. Engineered Bacteria labeled with Iridium(III) Photosensitizers for enhanced photodynamic immunotherapy of solid tumors. Angew Chem Int Ed Engl. 2023;62(43):e202310158.37668526 10.1002/anie.202310158
201. Li W Zhang Z Liu J Nanodrug-loaded Bifidobacterium bifidum conjugated with anti-death receptor antibody for tumor-targeted photodynamic and sonodynamic synergistic therapy Acta Biomater 2022 146 341 56 10.1016/j.actbio.2022.05.016 35580829
Li W, Zhang Z, Liu J, et al. Nanodrug-loaded Bifidobacterium bifidum conjugated with anti-death receptor antibody for tumor-targeted photodynamic and sonodynamic synergistic therapy. Acta Biomater. 2022;146:341–56.35580829 10.1016/j.actbio.2022.05.016
202. Li H Pei P He Q Nanozyme-coated Bacteria Hitchhike on CD11b + Immune cells to Boost Tumor Radioimmunotherapy Adv Mater 2024 36 8 2309332 10.1002/adma.202309332
Li H, Pei P, He Q, et al. Nanozyme-coated Bacteria Hitchhike on CD11b + Immune cells to Boost Tumor Radioimmunotherapy. Adv Mater. 2024;36(8):2309332.10.1002/adma.202309332
203. Wang W Zhang L Zhang Y A self-adaptive pyroptosis inducer: optimizing the Catalytic Microenvironment of nanozymes by membrane-adhered microbe enables Potent Cancer Immunotherapy Adv Mater 2024 36 14 e2310063 10.1002/adma.202310063 38153294
Wang W, Zhang L, Zhang Y, et al. A self-adaptive pyroptosis inducer: optimizing the Catalytic Microenvironment of nanozymes by membrane-adhered microbe enables Potent Cancer Immunotherapy. Adv Mater. 2024;36(14):e2310063.38153294 10.1002/adma.202310063
204. Chen H Zhao Y Applications of light-responsive systems for Cancer Theranostics ACS Appl Mater Interfaces 2018 10 25 21021 34 10.1021/acsami.8b01114 29648777
Chen H, Zhao Y. Applications of light-responsive systems for Cancer Theranostics. ACS Appl Mater Interfaces. 2018;10(25):21021–34.29648777 10.1021/acsami.8b01114
205. Han D Liu X Wu S Metal organic framework-based antibacterial agents and their underlying mechanisms Chem Soc Rev 2022 51 16 7138 69 10.1039/D2CS00460G 35866702
Han D, Liu X, Wu S. Metal organic framework-based antibacterial agents and their underlying mechanisms. Chem Soc Rev. 2022;51(16):7138–69.35866702 10.1039/D2CS00460G
206. Li Y Liu X Li B Zheng Y Wu S Near-Infrared Light Triggered Phototherapy and Immunotherapy for Elimination of Methicillin-Resistant Staphylococcus aureus Biofilm infection on Bone Implant ACS Nano 2020 14 7 8157 70 10.1021/acsnano.0c01486 32585104
Li Y, Liu X, Li B, Zheng Y, Wu S. Near-Infrared Light Triggered Phototherapy and Immunotherapy for Elimination of Methicillin-Resistant Staphylococcus aureus Biofilm infection on Bone Implant. ACS Nano. 2020;14(7):8157–70.32585104 10.1021/acsnano.0c01486
207. Zheng Q Liu X Zheng Y The recent progress on metal-organic frameworks for phototherapy Chem Soc Rev 2021 50 8 5086 125 10.1039/D1CS00056J 33634817
Zheng Q, Liu X, Zheng Y, et al. The recent progress on metal-organic frameworks for phototherapy. Chem Soc Rev. 2021;50(8):5086–125.33634817 10.1039/D1CS00056J
208. Zhang W Ding X Cheng H Dual-targeted gold nanoprism for recognition of early apoptosis, dual-model imaging and Precise Cancer Photothermal Therapy Theranostics 2019 9 19 5610 25 10.7150/thno.34755 31534506
Zhang W, Ding X, Cheng H, et al. Dual-targeted gold nanoprism for recognition of early apoptosis, dual-model imaging and Precise Cancer Photothermal Therapy. Theranostics. 2019;9(19):5610–25.31534506 10.7150/thno.34755
209. Wu D Xu S Zhang X A Near-Infrared laser-triggered size-shrinkable nanosystem with in situ drug release for Deep Tumor Penetration ACS Appl Mater Interfaces 2021 13 14 16036 47 10.1021/acsami.1c00022 33733732
Wu D, Xu S, Zhang X, et al. A Near-Infrared laser-triggered size-shrinkable nanosystem with in situ drug release for Deep Tumor Penetration. ACS Appl Mater Interfaces. 2021;13(14):16036–47.33733732 10.1021/acsami.1c00022
210. Overchuk M Zheng G Overcoming obstacles in the tumor microenvironment: recent advancements in nanoparticle delivery for cancer theranostics Biomaterials 2018 156 217 37 10.1016/j.biomaterials.2017.10.024 29207323
Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials. 2018;156:217–37.29207323 10.1016/j.biomaterials.2017.10.024
211. Dai Y Xu C Sun X Chen X Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment Chem Soc Rev 2017 46 12 3830 52 10.1039/C6CS00592F 28516983
Dai Y, Xu C, Sun X, Chen X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017;46(12):3830–52.28516983 10.1039/C6CS00592F
212. Yuan Z Liu X Ling J In situ-transition nanozyme triggered by tumor microenvironment boosts synergistic cancer radio-/chemotherapy through disrupting redox homeostasis Biomaterials 2022 287 121620 10.1016/j.biomaterials.2022.121620 35709558
Yuan Z, Liu X, Ling J, et al. In situ-transition nanozyme triggered by tumor microenvironment boosts synergistic cancer radio-/chemotherapy through disrupting redox homeostasis. Biomaterials. 2022;287:121620.35709558 10.1016/j.biomaterials.2022.121620
213. Sun D Wang Z Zhang P Ruthenium-loaded mesoporous silica as tumor microenvironment-response nano-fenton reactors for precise cancer therapy J Nanobiotechnol 2021 19 1 98 10.1186/s12951-021-00848-x
Sun D, Wang Z, Zhang P, et al. Ruthenium-loaded mesoporous silica as tumor microenvironment-response nano-fenton reactors for precise cancer therapy. J Nanobiotechnol. 2021;19(1):98.10.1186/s12951-021-00848-x
214. Xu Q Lan X Lin H Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors Wiley Interdiscip Rev Nanomed Nanobiotechnol 2023 15 1 e1842 10.1002/wnan.1842 35989568
Xu Q, Lan X, Lin H, et al. Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15(1):e1842.35989568 10.1002/wnan.1842
215. Pitt J Marabelle A Eggermont A Soria J Kroemer G Zitvogel L Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy Ann Oncol 2016 27 8 1482 92 10.1093/annonc/mdw168 27069014
Pitt J, Marabelle A, Eggermont A, Soria J, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92.27069014 10.1093/annonc/mdw168
216. Casas A Di Venosa G Hasan T Batlle A Mechanisms of resistance to photodynamic therapy Curr Med Chem 2011 18 16 2486 515 10.2174/092986711795843272 21568910
Casas A, Di Venosa G, Hasan T, Batlle A. Mechanisms of resistance to photodynamic therapy. Curr Med Chem. 2011;18(16):2486–515.21568910 10.2174/092986711795843272
217. Maas A Carter S Wileyto E Tumor vascular microenvironment determines responsiveness to photodynamic therapy Cancer Res 2012 72 8 2079 88 10.1158/0008-5472.CAN-11-3744 22374982
Maas A, Carter S, Wileyto E, et al. Tumor vascular microenvironment determines responsiveness to photodynamic therapy. Cancer Res. 2012;72(8):2079–88.22374982 10.1158/0008-5472.CAN-11-3744
218. Tang W Zhen Z Wang M Red blood cell-facilitated photodynamic therapy for Cancer Treatment Adv Funct Mater 2016 26 11 1757 68 10.1002/adfm.201504803 31749670
Tang W, Zhen Z, Wang M, et al. Red blood cell-facilitated photodynamic therapy for Cancer Treatment. Adv Funct Mater. 2016;26(11):1757–68.31749670 10.1002/adfm.201504803
219. Correia J Rodrigues J Pimenta S Dong T Yang Z Photodynamic therapy review: principles, photosensitizers, applications, and future directions Pharmaceutics 2021 13 9 1332 10.3390/pharmaceutics13091332 34575408
Correia J, Rodrigues J, Pimenta S, Dong T, Yang Z. Photodynamic therapy review: principles, photosensitizers, applications, and future directions. Pharmaceutics. 2021;13(9):1332.34575408 10.3390/pharmaceutics13091332
220. Fu S Zhang R Gao Y Programming the lifestyles of engineered bacteria for cancer therapy Natl Sci Rev 2023 10 5 nwad031 10.1093/nsr/nwad031 37056431
Fu S, Zhang R, Gao Y, et al. Programming the lifestyles of engineered bacteria for cancer therapy. Natl Sci Rev. 2023;10(5):nwad031.37056431 10.1093/nsr/nwad031
221. Pei P Zhang Y Jiang Y Pleiotropic immunomodulatory functions of Radioactive inactivated bacterial vectors for enhanced Cancer Radio-Immunotherapy ACS Nano 2022 16 7 11325 37 10.1021/acsnano.2c04982 35819107
Pei P, Zhang Y, Jiang Y, et al. Pleiotropic immunomodulatory functions of Radioactive inactivated bacterial vectors for enhanced Cancer Radio-Immunotherapy. ACS Nano. 2022;16(7):11325–37.35819107 10.1021/acsnano.2c04982
222. Canale F Basso C Antonini G Metabolic modulation of tumours with engineered bacteria for immunotherapy Nature 2021 598 7882 662 6 10.1038/s41586-021-04003-2 34616044
Canale F, Basso C, Antonini G, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature. 2021;598(7882):662–6.34616044 10.1038/s41586-021-04003-2
223. Abedi M Yao M Mittelstein D Ultrasound-controllable engineered bacteria for cancer immunotherapy Nat Commun 2022 13 1 1585 10.1038/s41467-022-29065-2 35332124
Abedi M, Yao M, Mittelstein D, et al. Ultrasound-controllable engineered bacteria for cancer immunotherapy. Nat Commun. 2022;13(1):1585.35332124 10.1038/s41467-022-29065-2
224. Savage T Vincent R Rae S Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity Sci Adv 2023 9 10 eadc9436 10.1126/sciadv.adc9436 36888717
Savage T, Vincent R, Rae S, et al. Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity. Sci Adv. 2023;9(10):eadc9436.36888717 10.1126/sciadv.adc9436
225. Min J Kim H Park J Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli Mol Imaging Biol 2008 10 1 54 61 10.1007/s11307-007-0120-5 17994265
Min J, Kim H, Park J, et al. Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol. 2008;10(1):54–61.17994265 10.1007/s11307-007-0120-5
226. Min J Nguyen V Kim H Hong Y Choy H Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals Nat Protoc 2008 3 4 629 36 10.1038/nprot.2008.32 18388945
Min J, Nguyen V, Kim H, Hong Y, Choy H. Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. Nat Protoc. 2008;3(4):629–36.18388945 10.1038/nprot.2008.32
227. Liu X Guo Y Sun Y Comparison of Anticancer activities and Biosafety between Salmonella enterica Serovar Typhimurium ∆ppGpp and VNP20009 in a Murine Cancer Model Front Microbiol 2022 13 914575 10.3389/fmicb.2022.914575 35847095
Liu X, Guo Y, Sun Y, et al. Comparison of Anticancer activities and Biosafety between Salmonella enterica Serovar Typhimurium ∆ppGpp and VNP20009 in a Murine Cancer Model. Front Microbiol. 2022;13:914575.35847095 10.3389/fmicb.2022.914575
228. Liu Z Lim SH Min JJ Jung S Synergistic Antitumor Effect of Combined Radiotherapy and Engineered Salmonella typhimurium in an intracranial sarcoma mouse model Vaccines Jul 2023 23 7 1275 10.3390/vaccines11071275
Liu Z, Lim SH, Min JJ, Jung S. Synergistic Antitumor Effect of Combined Radiotherapy and Engineered Salmonella typhimurium in an intracranial sarcoma mouse model. Vaccines Jul. 2023;23(7):1275.10.3390/vaccines11071275
229. Li H Pei P He Q Nanozyme-coated Bacteria Hitchhike on CD11b Immune cells to Boost Tumor Radioimmunotherapy Adv Mater 2024 36 8 e2309332 10.1002/adma.202309332 37934114
Li H, Pei P, He Q, et al. Nanozyme-coated Bacteria Hitchhike on CD11b Immune cells to Boost Tumor Radioimmunotherapy. Adv Mater. 2024;36(8):e2309332.37934114 10.1002/adma.202309332
230. Zhang Y Ji W He L E. Coli Nissle 1917-Derived minicells for targeted delivery of Chemotherapeutic Drug to hypoxic regions for Cancer Therapy Theranostics 2018 8 6 1690 705 10.7150/thno.21575 29556350
Zhang Y, Ji W, He L, et al. E. Coli Nissle 1917-Derived minicells for targeted delivery of Chemotherapeutic Drug to hypoxic regions for Cancer Therapy. Theranostics. 2018;8(6):1690–705.29556350 10.7150/thno.21575
231. Cunningham C Nemunaitis J A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer Hum Gene Ther 2001 12 12 1594 6 11529249
Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Hum Gene Ther. 2001;12(12):1594–6.11529249
232. Bullman S Pedamallu C Sicinska E Fusobacterium Analysis of persistence and antibiotic response in colorectal cancer Science 2017 358 6369 1443 8 10.1126/science.aal5240 29170280
Bullman S, Pedamallu C, Sicinska E, et al. Fusobacterium Analysis of persistence and antibiotic response in colorectal cancer. Science. 2017;358(6369):1443–8.29170280 10.1126/science.aal5240
233. Bao Y Cheng Y Liu W Luo W Zhou P Qian D Bacteria-based synergistic therapy in the Backdrop of Synthetic Biology Front Oncol 2022 12 845346 10.3389/fonc.2022.845346 35444948
Bao Y, Cheng Y, Liu W, Luo W, Zhou P, Qian D. Bacteria-based synergistic therapy in the Backdrop of Synthetic Biology. Front Oncol. 2022;12:845346.35444948 10.3389/fonc.2022.845346
234. Hosseinidoust Z Mostaghaci B Yasa O Park B Singh A Sitti M Bioengineered and biohybrid bacteria-based systems for drug delivery Adv Drug Deliv Rev 2016 106 27 44 10.1016/j.addr.2016.09.007 27641944
Hosseinidoust Z, Mostaghaci B, Yasa O, Park B, Singh A, Sitti M. Bioengineered and biohybrid bacteria-based systems for drug delivery. Adv Drug Deliv Rev. 2016;106:27–44.27641944 10.1016/j.addr.2016.09.007
235. Schultz M Clinical use of E. Coli Nissle 1917 in inflammatory bowel disease Inflamm Bowel Dis 2008 14 7 1012 8 10.1002/ibd.20377 18240278
Schultz M. Clinical use of E. Coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(7):1012–8.18240278 10.1002/ibd.20377
236. Różańska D Regulska-Ilow B Choroszy-Król I Ilow R The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases Postepy Hig Med Dosw 2014 68 1251 6 10.5604/17322693.1127882
Różańska D, Regulska-Ilow B, Choroszy-Król I, Ilow R. The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases. Postepy Hig Med Dosw. 2014;68:1251–6.10.5604/17322693.1127882
237. MALMGREN R Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration Cancer Res 1955 15 7 473 8 13240693
MALMGREN R. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 1955;15(7):473–8.13240693
